Nucleic acid inhibitors and uses thereof

By inhibiting the interaction between LINC02362 and EZH2 using a nucleic acid inhibitor, the chemoresistance in multiple myeloma is overcome, enhancing drug sensitivity and improving treatment outcomes.

WO2026235637A1PCT designated stage Publication Date: 2026-11-12NANYANG TECH UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/SG2026/050293
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-08
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current cancer therapies, particularly for multiple myeloma, face challenges due to high genetic heterogeneity leading to treatment resistance and relapse, with the non-canonical NF-KB pathway contributing to chemoresistance, and the role of its downstream targets remaining unclear.

Method used

Administering a nucleic acid inhibitor of LINC02362 to inhibit its interaction with EZH2, a key component in the PRC2 complex, to target and disrupt the oncogenic pathway, thereby overcoming chemoresistance.

Benefits of technology

The nucleic acid inhibitor effectively reduces cancer cell proliferation, enhances sensitivity to chemotherapeutic drugs, and improves survival rates by disrupting the PLUM-EZH2 interaction, thus addressing treatment resistance in multiple myeloma.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SG2026050293_12112026_PF_FP_ABST
    Figure SG2026050293_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates, in general terms, to the field of molecular biology Specifically, the invention relates to nucleic acid inhibitors and their use in treating cancers. In one embodiment, the nucleic acid inhibitor is a steric antisense oligonucleotide (ASO) that is capable of inhibiting the interaction between a NF-KB / p52 regulated long non-coding RNA (IncRNA), LINC02362, and an Enhancer of Zeste Homolog 2 (EZH2) polypeptide. In this specification, the LINC02362 is also termed as PLUM (PRC2 associated LncRNA regulating QPR in MM). The steric ASO may bind to PLUM, which may cause the PLUM-EZH2 interaction to be inhibited, and may further re-sensitize the multiple myeloma (MM) cells to drug treatment or chemotherapy.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] NUCLEIC ACID INHIBITORS AND USES THEREOFTechnical field

[0002] The present invention relates, in general terms, to the field of molecular biology. In particular, the invention relates to nucleic acid inhibitors and their uses in treating cancers.

[0003] Background

[0004] Cancer remains a leading cause of morbidity and mortality worldwide, characterised by the uncontrolled proliferation and spread of abnormal cells. Conventional cancer therapies have historically included surgery, radiotherapy, and chemotherapy, each of which seeks to eliminate or control tumour growth through different mechanisms.

[0005] Multiple myeloma (MM) is the second most common haematological malignancy that displays a poor prognosis despite significant advances in novel treatment strategies. The current treatment regimen comprising Velcade® (bortezomib) with Revlimid (lenalidomide) and dexamethasone (VRd regimen), in combination with an antibody treatment. However, it remains incurable due to high genetic heterogeneity driving treatment resistance and relapse. There is therefore an unmet clinical need to develop targeted therapies which can overcome treatment resistance and relapse in MM patients.

[0006] Genetic mutations leading to the dysregulation of oncogenic pathways have been implicated to contribute to the chemoresistance of MM and other cancer patients. One such aberrantly activated pathway is the non-canonical NF-KB (ncNF-KB) pathway, which was found to potentiate oncogenic transcription through reprogramming of the myeloma epigenome. However, the role of ncNF-KB signaling and its downstream targets contributing to the chemoresistance of MM and other cancers remains unknown.

[0007] It would be desirable to overcome or ameliorate at least one of the above-described problems, or at least to provide a useful alternative.Summary

[0008] Disclosed herein is a method of treating a cancer in a subject in need thereof, comprising administering a pharmaceutically effective amount of a nucleic acid inhibitor of a long noncoding RNA (IncRNA), LINC02362, wherein the nucleic acid inhibitor is capable of inhibiting the interaction between LINC02362 and an Enhancer of Zeste Homolog 2 (EZH2) polypeptide.

[0009] Disclosed herein is a nucleic acid inhibitor of LINC02362, wherein the nucleic acid inhibitor of LINC02362 comprises, encodes, or binds to a nucleic acid sequence of having at least 70% sequence identity to a nucleic acid sequence in any one of SEQ ID NOs: 19-20, or a complementary sequence thereof.

[0010] Disclosed herein is a method of detecting a cancer with drug resistance in a subject, the method comprising: (a) detecting the level of expression of EZH2 and / or LINC02362 in a sample from the subject, wherein an increased expression of EZH2 and / or LINC02362 as compared to a reference indicates that the subject is likely to have the cancer with drug resistance; and (b) administering a pharmaceutically effective amount of a nucleic acid inhibitor of LINC02362 to the subject found likely to have the cancer with drug resistance.

[0011] Disclosed herein is a use of a nucleic acid inhibitor of LINC02362 in the manufacture of a medicament for treating a subject with a cancer.

[0012] Disclosed herein is a nucleic acid inhibitor of LINC02362, for use in the treatment of a cancer.

[0013] Disclosed herein is a pharmaceutical composition comprising a nucleic acid inhibitor of LINC02362 for use in the treatment of a cancer.

[0014] Disclosed herein is a use of a pharmaceutical composition comprising nucleic acid inhibitor of LINC02362 in the manufacture of a medicament for a cancer.

[0015] Brief description of the drawings

[0016] Embodiments of the present invention will now be described, by way of non-limitingexample, with reference to the drawings in which:

[0017] Figure 1. PLUM is a p52-regulated, oncogenic IncRNA enriched in high-risk MM subtypes carrying NF-KB activation, (a) Plot showing the coding and non-coding genes downregulated upon p52-KD in KMS11 cells (N = 3; 2-sided Wald Test). Red dots: coding transcripts; Blue dots: non-coding transcripts. Size of the dots: Number of high-risk MM subtypes showing upregulation in NF-KB+ samples, (b) Violin plot showing the expression level of PLUM in patient samples divided into 4 aggressive subtypes and NF-KB activity (- / +): Iq gain (N = 7 / 32), HRD-low TP53 (N = 6 / 21), MAF (N = 14 / 50), and PR (N = 33 / 7). Pairwise and global p-values obtained using two-sided Wald (DESeq2) and Kruskal-Wallis (total N = 170), respectively, (c) Heat map representing gene expression dynamics of p52-regulated IncRNAs and other genes across MAF and HRD low TP53 patient samples split by NF-KB activity identified in DESeq2 (2-sided Wald, FDR < = 0.1) using RNA-seq data Highlight: green-PLUM and black-other p52-regulated IncRNAs. Dynamics: blue-depleted, red-enriched and white-non-significant (ns) with relation to p52 KD and NF-KB+ / -. PLUM marked in green. N=3. (d) Violin plot showing PLUM expression in VRd non-responsive (N = 19) and responsive patients (N=225). Pairwise-comparison for variance-stabilized transformed (VST) expression was determined by two-sided Wilcoxon rank-sum test (total N = 244); median and quartiles indicated with p-value = 0.018. (e) Expression level (log2 TPM) of top p52-regulated IncRNAs (Inc-NTMTl, MALT 1 -AS 1, NR2F2-AS1 wAPLUM) in 51 pan-cancer cell types from CCLE datasets (Others, N = 638, MM, N=20). Lower and upper hinges correspond to first and third quartiles. Central value corresponds to median Lower and upper whiskers correspond to smallest and largest value. Outliers beyond 1.5* 1QR indicated. Pair wise and global p-values obtained using two-sided Wilcoxon and Kruskal-Wallis, respectively, (p-values for lnc-NTMT1-2: 0.0022, MALT1-AS1: 0.0012, NRF2-AS1: 0.01, PLUM: 1.1e-12). (f)Line diagram showing isoforms of PLUM identified by 5’ RACE (Red boxes: exons, red lines: introns) and 6 isoforms of LINC02362 available in Ensemble database (Blue boxes: exons; blue lines: introns), (g) Micrographs localization of PLUM using RNA-FISH probe (Fluor®-Red635) and nuclei stained with DAPI (Blue). Arrows: enriched spots for PLUM. Inset: colocalization of red color (Fluor®Red635 for PLUM) with blue color (DAP1 for nuclei). Scale bar: 20 pm and N = 3 biological replicates.

[0018] Figure 2. Oncogenic PLUM confers chemoresistance in MM. (a) Graphs representing proliferation rate (mean ± SEM) of VL-PLUM overexpressed KMS11 and LP1 cells relativeto vector control (N=3, two-way ANOVA; p-values - KMS11: 0.0006 and LP1: 0.0097). (b) Box plot showing percentage of live and apoptotic cells (Annexin V staining) (mean ± SEM) in sh-scramble versus \-PLUM multiple myeloma cell lines (MMCLs) (KMS11 and LP1) at day 6 post transduction (N = 3, two-sided multiple t-test; p-values-KMSl 1 -scramble: 0.001, KMSll-sh2: 0.001, KMSll-sh7: 0.001, LPl-scramble: 0.04, LPl-sh2: 0.001, LP1-sh7: 0.001). (c, d) Drug sensitivity IC50 survival curve (mean percentage ± SEM) for Vector control (VC) and YE-PLUM overexpressed NF-KB+ mutant MMCLs (KMS11 and LP1) in response to BTZ treatment for 24 h and Len treatment for 4 days respectively (N = 3, two-way ANOVA, p-values for BTZ treatment-KMSll: 0.0006 and LP1: 0.0001, p-values for Len treatment-KMSll: 0.045 and LP1: 0.0027). (e, f) Drug sensitivity 1C50 survival curve (mean percentage ± SEM) for vector control (VC) and YE-PLUM overexpressed NF-KB-non-mutant MMCLs (XG-7 and H929) in response to BTZ treatment for 24 h and Len treatment for 4 days, respectively (N=3, two-way ANOVA; p-values for BTZ treatment-XG-7: 0.0013 andH929: 0.023), p-values for Len treatment-XG-7: 0.043 andH929: 0.045).

[0019] (g) Graphical representation of the in vivo tumour xenograft and BTZ treatment experiments performed using mice engrafted with VC and PLUM OE KMS11 cells, (h) Tumour growth plot depicting average tumour volume (mean ± SEM) from mice engrafted with control (VC) and PLUM OE KMS11 cells followed by treatment with DMSO and BTZ as shown in this figure (g). (N = 5 mice / group; two-sided multiple t-test; p-values - Control + DMSO versus Control + BTZ: 0.0001, Control + DMSO versus PLUM OE + DMSO: 0.0004, PLUM OE +DMSO versus PLUMOE + BTZ: 0.0001 and PL UM OE + DMSO versus Control + BTZ: 0.0002. (i) Kaplan-Meier survival plot of mice xenografts as mentioned in (2 h). Two-sided log-rank (Mantel-Cox) test; p-values-Control + DMSO versus Control + BTZ: 0.0045, Control + BTZ versus PLUM OE + BTZ: 0.005, Control + DMSO versus PLUM OE + DMSO: 0.036.

[0020] Figure 3. PLUM interacts directly with EZH2 via exon 7 to regulate its activity and stability, (a) Proliferative rate of 8 exon deletion mutants of PLUM overexpressed KMS11 cells compared to FL PLUM and vector control (VC) Red box: PLUM mutants with no proliferative phenotype compared to VC (N = 2 biological replicates), (b) Drug sensitivity 1C50 survival curve of 8 exon deletion mutants of PL UM overexpressed cells compared to EE-PLUM and VC post BTZ treatment (24 h). Red box: PLUM mutants sensitive to BTZ treatment compared to VC (N = 2 biological replicates), (c) Strategy used to perform RNA protein pulldown assay followed by MS-LFQ analysis using EE-PLUM, AExonl andAExon7 PLUM and nuclear lysate of KMS11 cells, (d, e) Volcano plots showing differentially bound protein to YL-PLUM compared to AExonl and AExon7 PLUM, respectively. Red dot: EZH2 protein. N=4, MS analysis was done with fold change >2 and p-value < 0.01 determined by two-sided unpaired t-test. (f) Micrographs showing colocalization of EZH2 with PLUM. Framel: Bright field, Frame2: RNA-FISH for PLUM (Fluor®Red), Frame3: IF for EZH2 (Green) and Framed: merged frame for frames 2 and 3. Nuclei stained with DAPI (Blue). Inset / arrows: magnified colocalization spot forEZH2 and PLUM. Scale bars: 20pm; N=3 biological replicates with 3 frames each, (g) RIP-qPCR validation of PL UM (mean ± SEM) with EZH2 and IgG antibody (N = 3, two-sided unpaired student’s t-test; p-value: 0.0003). (h) Binding of PRC2 complex proteins (EZH2, EED and SUZ12) with FL-PLUM, AExonl and AExon7 PLUM mutants. IRE transcript: negative control and GAPDH: loading control (N = 2 biological replicates), (i) Levels of EZH2, EED and SUZ12 in sh-scramble, sh-PLUM KD cells and FL-F’ZMIf, PLUM- AExonl, PLUM-AExon7 mutants overexpressed cells (N = 3 biological replicates), (j) Expression levels of EZH2 in scramble, s\\ -PLUM and sh7-PLUM KD cells at different time point of treatment with cycloheximide (100 pg / ml) (N = 2 biological replicates), (k) Levels of EZH2 protein in scramble, sh2-PLUM and sh7-PLUM KD cells at 16 h of treatment with MG132 (20 pM). DMSO: vehicle control (N = 2 biological replicates). (1) Levels of total EZH2, pEZH2-T345, H3K27me3, H3, CDKN2A, CDKN2B, CDKN2A, total CDK1 / 2, pCDKl proteins in control and EZH2 overexpressed cells (+MG132) post treatment with degradative NC-ASO, ASO-glV and ASO-gV for 36 h (N = 3 biological replicates).

[0021] Figure 4. PLUM-EZH2 interaction is important for PRC2 complex formation, (a) Levels of EED and SUZ12 protein co-immunoprecipitated by EZH2 antibody in scramble and sh2-PLUM KD KMS11 cells. (+MG132-20 pM). IgG: IP control; GAPDH: input protein loading control (N = 3 biological replicates), (b) Levels of EED and SUZ12 protein pulled down by FL-PLUM, AExonl PLUM, AExon7 PLUM transcripts from nuclear lysate of scramble and sh-EZH2 KD KMS11 cells. IRE: negative control and GAPDH: input protein loading control (N = 1). (c) Levels of EZH2 and SUZ12 protein pulled down by FL-PLUM, AExonl PLUM, AExon7 PLUM transcripts from nuclear lysate of scramble and sh-EED KD KMS11 cells. IRE: negative control and GAPDH: input protein loading control (N = 1). (d) Expression levels of EZH2 and EED protein pulled by FL-PLUM, AExonl PLUM, AExon7 PLUM transcripts from nuclear lysate of scramble and sh-SUZ12 KD KMS11 cells. IRE: negative control and GAPDH: input protein loading control (N = 1) (e) Dockedstructure of exon7-PLUM and EZH2 protein. Interacting residues on EZH2 marked as Green: 488-498 aa; Red: 562-575 aa and Blue: 586-602 aa. (f) Graphical representation of the EZH2 protein with all the domains marked in different colors. (*) sign: reported residues having RNA-binding role. Mutants generated: HA-Mutl: K39A, HA-Mut2: F32AD36AK39A, HA-Mut3:-F32AR34AD36AK39A and HA-Mut4: PRKKKR489-494NAAIRS. Tertiary structure of EZH2 protein with marked RNA-interacting residues in different color code. Green: F32-K39, Magenta: T345 (CDK1 / 2 phosphorylation site), Red: P489-R494 (disordered region), (g) Levels of EZH2 protein pulled down with FL-PLUM in + / - CDK1 inhibitor (R03306) cells. DMSO: vehicle control and GAPDH: input protein loading control (N = 2 biological replicates), (h) Levels of wild type HA-EZH2 and HA-EZH2 mutants (HA-Mutl: K39A, HA-Mut2: F32AD36AK39A, HA-Mut3: F32AR34AD36AK39A and HA-Mut4: PRKKKR489-494NAAIRS) pulled down with FL-PLUM. IB: HA antibody and GAPDH: input protein loading control (N = 2 biological replicates), (i) Levels of EED, SUZ12 and EZH2 protein co-immunoprecipitated by HA antibody in wild type HA-EZH2 and HA-EZH2 mutants (HA-Mutl: K39A, HA-Mut2: F32AD36AK39A, HAMut3: F32AR34AD36AK39A and HA-Mut4: PRKKKR489-494NAAIRS) overexpressed KMS11 cells. IgG: IP control and GAPDH: input protein loading control (N = 2 biological replicates).

[0022] Figure 5. Steric ASO-mediated disruption of PLUM-EZH2 interaction abrogates drug resistance in MM. (a-c) Top three docked model of FL-PL UM and EZH2 with interacting residues highlighted in space-filling format. Red arrows: Interacting exons of PLUM with EZH2 for all three models, (d) Hypothetical working model of steric ASOs (LNA + 2’MOE modified) inhibiting H3K27me3 activity through hindering the interaction between PLUM-EZH2. (e) RIP-qPCR validation of PLUM with EZH2 and IgG antibody in KMS11 treated with NC-ASO and steric ASOs (N = 3, mean % input ± SEM is plotted, p-values determined by two-sided unpaired student’s t-test; p-value — NC: 0.011, s-ASO-g4: 0.048, s-ASO-gll and s-ASO-gl2 p-value non-significant). (f) Levels of EED, SUZ12 and EZH2 co-immunoprecipitated by EZH2 antibody in NC-ASO and steric ASOs treated KMS11 cells. (+MG132-20 pM); IgG: IP control (N = 3 biological replicates), (g) Levels of EZH2, p-EZH2 T345, H3K27me3, H3, EED and SUZ12 proteins in NC-ASO and steric ASOs treated KMS 11 cells (N = 5 biological replicates), (h) Proliferation rate (mean ± SEM) of KMS11 cells treated with NC-ASO and steric ASOs till day4 (N=3, p-values determined by two-way ANOVA; p-values — NC Vs s-ASO-g4: 0.005, NC Vs s-ASO-gll: 0.0005 andNC Vs s-AS0-g12: 0.0005). (i) The percentage (mean ± SEM) of annexin+ cells and annexin-cells post treatment with steric ASOs (N=4, p-values determined by two-sided multiple t-test; p-values - NC-ASO: 0.0001, s-ASO-g4: non-significant, s-ASO-gll: 0.01, s-ASO-gl2: 0.0039). (j) Drug sensitivity IC50 survival curve (mean ± SEM) for steric ASOs treated KMS11 cells in response to BTZ treatment for 24 h and Len treatment for 4 days, respectively (N=3, p-values determined by two-way ANOVA; BTZ treatment p-values — NC-ASO Vs s-ASO-g4: non-significant, NC-ASO versus s-ASO-gll: 0.0001, NC-ASO versus s-ASO-gl2: 0.0001 and Len treatment p-values — NC-ASOVs s-ASO-g4: nonsignificant, NC-ASO Vs s-ASO-gll: 0.0007, NC-ASO versus s-ASO-gl2: 0.003). (k)Drug sensitivity 1C50 survival curve (mean ± SEM) for steric ASOs treated BTZ S / BTZ R cells in response to BTZ treatment for 24 h and Len S / Len R cells in response to Len treatment for 4 days respectively (N=3, p-values determined by two-way ANOVA; BTZ S / -ASO versus BTZ S / +ASO: 0.0001, BTZ R / -ASO versus BTZ R / +ASO; 0.0001, LenS / -ASO versus LenS / +ASO: 0.005, LenR / -ASO versus LenR / +ASO: 0.0001).

[0023] Figure 6. PLUM confers chemoresistance via activation of UPR pathway, (a) Heat map representing the differential gene expression (DEGs) for RNA sequencing 3 days post transduction in sh-scramble and sh2- / ’ / . LW KD KMS11 cells (n =3; 2-sided Wald test; adjusted p-value <= 0.05). (b) GSEA for UPR signatures using down DEGs from PLUM KD RNA-seq inKMSll cells. Enrichment Score and Ranked List Metric are depicted. NES: -1.68; FDR: 0.00353. (c) Levels of UPR master regulators (p-IREla, sXBP-1, p-eIF2a and ATF6a) in sh-scramble and PLUM KD NF-KB +MMCLS (KMS11, LP1, MM.1, S). Average quantified values marked below each blot (N=3 biological replicates and quantification was done using GelQuant. NET). (d) Level of UPR master regulators in PLUM overexpressed cells relative to vector control inNF-KB+ mutant MMCLs (KMS11, LP1, MM.1. S). Average quantified values marked below each blot (N = 3 biological replicates and quantification was done using Gel-Quant. NET). (e) Proliferation rate (mean OD± SEM) of PLUM overexpressed KMS 11 cells transduced with sh-scramble and shl / sh2 IRE la (N=3, p-values determined by two-way ANOVA; p-values — VC versus PLUMOE: 0.0008, PLUMOE versus PLUM OE + scramble: non-significant, PLUM OE versus PLUM OE + shl IREla: 0.0002, PLUM OE versus PLUM OE + sh2 IREla: 0.0003). (f, g) Drug sensitivity IC50 curve (mean ± SEM) for PLUM overexpressed KMS 11 cells transduced with sh-scramble and shl / sh2 IREla in response to BTZ treatment for 24 h and Len treatment for 4 days respectively (N=3, p-values were determined by two-way ANOVA; BTZ treatment: VCversus PLUMOE'. 0.0001, PLUMOE versus PLUMOE + scramble: non-significant, PLUM OE versus PLUM OE+shl IREla: 0.0001, PLUM OE versus PLUM OE + sh2 IREla: 0.0001; Len treatment: VC versus PLUM OE: 0.001, PLUM OE versus PLUM OE + scramble: non-significant, PLUM OE versus PLUM OE + shl IREla: 0.0001, PLUM OE versus PLUM OE + sh2 IREla: 0.0001). (h) Levels of UPR master regulators in BTZ (RPMI8226), Len (KMS11) and Dexa (MM 1 R) acquired resistant cell lines versus parental sensitive cells. Average quantified values marked below each blot. (N = 2 biological replicates and quantification was done using Gel-Quant. NET) (i, j) Drug sensitivity IC50 curve for sh-scramble versus sh-IRElaKD cells in BTZ-R 8226 and Len-R KMS 11 cells in response to BTZ treatment for 24 h and Len treatment for 4 days, respectively (N = 2 biological replicates).

[0024] Figure 7. Hyperm ethylation of FOXO3 and ZFP36 via PLUM-mediated EZH2 activity promotes myeloma progression and chemoresistance, (a) EZH2 and H3K27me3 binding at transcription start sites (TSS) along with loci displaying differential H3K27me3 marks in sh-scramble and shl-PLUM KMS11 cells (N = 3 biological replicates), (b) Enriched biological processes GO terms associated with significantly upregulated genes displaying significant loss of H3K27me3 at their TSSs following PLUM-KD. (c) Genome browser visualization for the FOXO3 and ZFP36 loci. Tracks: EZH2 ChlP-seq (blue); H3K27me3 ChlP-seq: Control (brown) and PLUM KD (orange), (d, e) ChlP-qPCR validation (mean ± SEM) for FOXO3 and ZFP36 TSS region with H3K27me3 antibody in BTZ-S versus BTZ-R cells and Len-S versus Len-R cells, respectively (N = 3 biological replicates, two-sided unpaired student’s t-test, p-values mentioned in the plot), (f) Levels ofFOXO3 and ZFP36 protein in BTZ-R, Len-R, Dexa-R and their parental sensitive cell lines (N = 3 biological replicates), (g, h) ChIP qPCR validation forFOXO3 and ZFP36 TSS region with H3K27me3 antibody in BTZ resistant and Len resistant cells, respectively, treated with and without s-ASO-gl2 for 24 h (N = 2 biological replicates) (i) Levels of FOXO3 and ZFP36 protein in BTZ-R, Len-R, Dexa-R cell lines treated with and without steric s-ASO- l2 for 24 h (N=2 biological replicates) (j, k) Levels of UPR master regulators in sh-scramble versus sh-FOXO3 and sh-ZFP36 cells, respectively. Average quantified values marked below each blot (N = 3 biological replicates and quantification done using GelQuant. NET). (1) Tumour growth plot depicting average tumour volume (mean ± SEM) from mice engrafted with PLUM OE KMS11 cells under different treatment groups (DMSO+NC-ASO; s-ASO-gl2; BTZ; s-ASO-gl2 + BTZ) (N = 6 mice per condition; two-sided multiple t-test; p-values —NC-ASO+ DMSO versus s-ASO-gl2: 00009, NC-ASO+ DMSO versus BTZ: <0.0001, NC-ASO+ DMSO versus BTZ + sAS0-gl2: <0.0001, s-AS0-gl2 versus BTZ + s-ASO-gl2: 0.005, BTZ versus BTZ + s-ASO-gl2: 0.001). (m) Kaplan-Meier conditional survival plot of mice xenografts as mentioned in (1). N = 6 mice per condition; two-sided log-rank (Mantel-Cox) test; p-values — NCASO+DMSO versus s-ASO-gl2: 0.0015, BTZ versus BTZ+s-ASO-gl2: 0.0013, NCASO+DMSO versus BTZ: 0.0015, NC-ASO+DMSO versus BTZ+s-ASO-gl2: 0.0009. (n) Graphical representation of the working model: PLUM-EZH2 interaction drives formation of PRC2 complex altering stability and activity of EZH2 to mediate repression of tumour suppressor genes (FOXO3 and ZFP36), in turn inducing UPR pathway and confers chemoresistance in MM.

[0025] Figure 8. Identification and characterization of PLUM in MMCLs. (a) Level of NF-KB / p52 protein in empty vector (Lenti-V2) and Lenti-V2 CRISPR-p52 knock down MMCLs (KMS11 and LP1) (N=5 for KMS11 andN=3 for LP1). (b) Densitometric analysis (mean fold change ±SEM) for NF-KB / p52 band in western blots of Figure 8a. Analysis done using GelQuant. NET. The values for p52 band were normalised to GAPDH band (N=5 for KMS11 and N=3 for LP1; two-sided unpaired student’s! test; p-values - KMS11: 0.0001, LP1: 0.0001). (c) Endogenous expression level of PLUM in NF-KB+ (KMS11, LP1, MM.l. S, JJN3, RPMI8226, U266, EJM) and NF-KB- (XG-7, H929, MOLP8) MMCLs (N=2 biological replicates) (d) Gel image showing the bands for 5' / 3' RACE PCR products for PL UM which matched with isoform 201, 208 and 209 from Ensembl database (upon sequencing) in two MMCLs (KMS11 and LP1). (e) Relative abundance of different isoforms of PLUM in MMCLs (KMS11 and LP1) (N=2 biological replicates), (f) Graphical representation of the experimental design to study the coding potential of PLUM. Expression level of HA-PLUM and HA-Oct4 (positive control) protein probed with HA antibody showing no expression of PLUM protein or PLUM peptides, (g) Relative abundance of different isoforms of PLUM in the nuclear fraction (Top: Black bars) normalised to 7SK transcripts and in cytoplasmic fraction (Bottom: Red bars) normalised to cyto-c transcripts of three MMCLs (KMS 11, LP 1 and MM.1. S) (N=2 biological replicates), (h) Expression level of different isoforms of PLUM with control RNAs (7SK and cyto-c) in nuclear and cytosolic fractions of three MMCLs (KMS 11, LP1 and MM.l. S) (N=2 biological replicates), (i) Expression level of two exogenously overexpressed major isoforms of PLUM in nuclear and cytosolic fractions compared to VC transduced cells (N=2 biological replicates).

[0026] Figure 9. Functional characterization of PLUM in MMCLs. (a) Fold change enrichment (mean ± SEM) of -PLUM in overexpressed NF-KB+ MMCLs (KMS11, LP1 and MM.l. S) compared vector control (VC) (N=3, two-sided unpaired student’s t test; p-valucs- KMS11: 0.005, LP1: 0.005,MM.l. S: 0.005). (b) Proliferation rate (mean ± SEM) of MM.l. S cells overexpressed with FL-PLUM relative to VC (N=3, two-way ANOVA; p-values – MM.1.S: 0.0012). (c) Fold change enrichment of FL-PLUM (mean ± SEM) in overexpressed NF-KB- MMCLs (XG-7 and H929) compared VC (N=3, two-sided unpaired student’s t test; p-values - XG-7: 0.0008, H929: 0.0045). (d) Proliferation rate (mean ± SEM) of NF-KB- MMCLS (Xg-7 and H929) overexpressed with FL PLUM relative to VC till day 4 (N=3, two-way ANOVA; p-values – XG7: 0.0001, H929: 0.0019).

[0027] (e) Expression level (mean ± SEM) of FL PLUM in sh-scramble, sh2-PLUM and sh7-PLUM KD NF-KB+ MMCLS (KMS11, LP1 and MM.1 S) (N=3, two-sided unpaired student’s t test; p-values -KMS11: scramble versus sh2-PLUM: 0.0016, scramble versus sh7-PLUM: 0.0016; LP1: scramble versus s l-PLUM-. 0.0046, scramble versus sM-PLUM. 0.0001; MM.l. S: scramble versus sh2-PLUM: 0.0003, scramble versus sh7-PLUM: 0.0007). (f) Percentage of live and apoptotic cells (Annexin V+) (mean ± SEM) in sh-scramble versus sh-PLUM MM.l. S cells at day 6 post transduction (N=3, two-sided multiple t-test; p-values - MM.l. S scramble: 0.003, sh2: 0.001, sh7: 0.001). (g) Relative expression levels of PLUM (mean ± SEM) post treatment with degradative ASOs at concentrations of 50nM and 400nM. (N=3, two-sided impaired student’s t test; p-values - At 400nM, ASO-NC versus ASO-gIV: 0.0007, ASO-NC versus ASO-gV: 0.0006). (h) Proliferation rate (mean ± SEM) of NF-KB+ MMCLs (KMS11 and LP1) treated with NC-ASO and degradative ASOs (ASO-glV and ASO-gV) for 36 h (N=3, two-way ANOVA; p-values - For KMS11, NC-ASO versus ASO-glV: 0.04, NC-ASO versus ASO-gV: 0.013; For LP1, NC-ASO versus ASO-glV: 0.0004, NC-ASO versus ASO-gV: 0.001). (i) Proliferation rate (mean ± SEM) of XG-7 and H929 cells treated with NC-ASO and degradative ASO-glV / ASO-gV (N=3, two-way ANOVA; p-values – non-significant). (j) Percentage of live and apoptotic cells (AnnexinV+) (mean ± SEM) in NC-ASO and degradative ASO-glV, g-V treated NF-KB - MMCLs (XG-7 and H9292) (N=3, two-sided multiple t-test; p-values with biological replicates 0.001).

[0028] Figure 10. PLUM expression is correlated with chemoresistance in MMCLs. (a) Expression level (mean ± SEM) of PLUM in BTZ-R (RPMI8226), Len-R (KMS11) and Dexa-R (MM.1R) versus its parental sensitive cells (N=3, two-sided impaired student’s t test; p-values - BTZ-R versus BTZ-S: 0.0001, Len-R versus Len-S: 0.0017, Dexa-R versus Dexa-S: 0.0025). (b) Drug sensitivity IC50 survival curve (mean ± SEM) for PLUM overexpressed MM.l. S cell line compared to vector control in response to BTZ treatment for 24h and Len treatment for 4 days (N=3, two-way ANOVA; p-values - BTZ: 0.045 and Len: 0.043). (c, d) Drug sensitivity IC50 survival curve (mean ± SEM) for NC-ASO and degradative ASO (ASO-glV and ASO-gV) treated cells in response to BTZ treatment for 24h and Len treatment for 4 days in KMS 11 and LP 1 cells respectively (N=3, two-way ANOVA; p-values - For KMS11 BTZ treatment, NC-ASO versus ASO-glV: 0.005, NC-ASO versus ASO-gV: 0.0005; For KMS11 Len treatment, NC-ASO versus ASO-glV: 0.0005, NC-ASO versus ASO-gV: 0.0005; For LP1 BTZ treatment, NC-ASO versus ASO-glV: 0.0005, NC-ASO versus ASO-gV: 0.0005: ForLPl Len treatment, NC-ASO versus ASO-glV: 0.005, NC-ASO versus ASO-gV: 0.045).

[0029] (e, f). Drug sensitivity ICso survival curve (mean ± SEM) for NC-ASO and degradative ASO (ASO-glV and ASO-gV) treated cells in response to BTZ treatment for 24h and Len treatment for 4 days in XG-7 and H929 cells respectively (N=3, two-way ANOVA; p-values - ns: non-significant).

[0030] Figure 11. Mutagenesis design for PLUM expression construct and characterization of the activity of ASOs in MM cells, (a) Line diagram representing different exon deletion mutants of PLUM (Boxes: exons; Lines: introns; red boxes: deleted exons), generated by site-directed mutagenesis, (b) Proliferative rate of 8 exon deletion mutants of PLUM overexpressed LP1 cells compared to FL PLUM and vector control (VC). Red box: PLUM mutants with no proliferative phenotype compared to VC (N=2 biological replicates), (c) Drug sensitivity ICT survival curve of 8 exon deletion mutants o PLUM overexpressed LP1 cells compared to F L-PLU and VC post BTZ treatment (24h). Red box: PLUM mutants sensitive to BTZ treatment compared to VC (N=2 biological replicates), (d) RIP -qPCR validation ofT’LCTV / with EZH2 and IgG antibody in LP1 cells (N=2 biological replicates), (e) Immunoblots showing differential binding of PRC2 complex proteins (EZH2, EED and SUZ12) with FL PLU'v AExonl and AExon7 mutants of PLUM using BTZ-R 8226 nuclear lysates. IRE transcript: negative control; GAPDH: input protein loading control (N=2 biological replicates), (f) RNA-EMSA blot of purified WT-EED protein with biotinylated exonl and exon7 region of PLUM RNA. Labelled negative control (NC) RNA was used as control. RNA-EMSA blot of purified WT-EED protein with biotinylated exon 1 region and unlabelled exon 1 region (200X molar concentration) of PLUM RNA. (g) Expression level (mean fold change ± SEM) of PLUMm' shl-EZH2, M-EZII2 and s\\i-EZH2 KD cells compared to sh-scramble taken as 1 (N=3, two-sided unpaired student's t test; ns: non-significant). (h) Level of exogenously overexpressed EZH2 (pLJM-EZH2) protein in NC-ASO and degradative ASO (g-IV and g-V) treated NF-KB+ KMS11 cells at different time points of treatment with cycloheximide (lOOpg / ml) (N=2 biological replicates).

[0031] Figure 12. PLUM facilitates formation of PRC2 complex via direct interaction with the disordered region of EZH2. (a) Levels of EED and SUZ12 proteins co-immunoprecipitated (CoIP) by EZH2 antibody in sh-scramble and sh2- PLUMYM LP1 and BTZ-R 8226 cell lines post day 2 after selection. (+MG132-20pM); IgG: IP control, GAPDH: input protein loading control (N=2 biological replicates), (b) Expression level of EZH2, EED and SUZ12 proteins in sh-scramble and sh-EZH2 / EED / SUZ12 transduced KMS11 cells respectively. sh2 -knock down cells were used for RNA-protein pull down assay, (c) The docked structure of the T7T / A7-EZH2 complex generatedusing AlphaFold3. The colour shading of the structure represents the pTDDT confidence score of the structure. The pTM score (predicted TM-score for the full structure) is 0.35 and the ipTM (predicted TM-score of the interfaces between subunits) is 0.17. (d) Binding level of EZH2 protein pulled with FL PLUM in CDK1 inhibitor (Ro3306) treated BTZ-R 8226 cell line. DMSO: vehicle control, IRE transcript: negative control, GAPDH: input protein loading control (N=2 biological replicates), (e) RNA-EMSA blot of purified truncated WT EZH2 (E317-V522) and truncated Mut4-EZH2 (E317-PRKKR489-494NAAIRS-V522) protein with biotinylated exon 7 region of PLUM RNA. Labelled negative control (NC) RNA was used as control, (f) RNA-EMSA blot of purified truncated WT EZH2 (E317-V522) protein with biotinylated exon 7 region of PL UM and 200-fold molar excess of unlabelled exon 7 region of PLUM.

[0032] Figure 13. Steric ASOs mediated disruption of PLUM-EZH2 complex resensitize MMCLs to chemotherapeutic drugs, (a) RIP-qPCR validation of PLUM with EZH2 antibody compared to IgG antibody in KMS11 post treatment with NC-ASO and steric ASOs (s-ASO-g2, s-ASO-g3, s-ASO-g4, s-ASO-g6, s-ASO-g7, s-ASO-g8, s-ASO-g9, s-ASO-gll and s-ASO-gl2) for 3 days (N=2 biological replicates), (b) Level of EED and SUZ12 proteins co-immunoprecipitated (Co-IP) by EZH2 antibody in NC-ASO, s-ASO-g4, s-ASO-gll and s-ASO-gl2 treated BTZ-R 8226 cell line. (+MG132-20pM); IgG: IP control, GAPDH: input protein loading control (N=2 biological replicates), (c) Expression level (mean ± SEM) of PLUMm' KMS11 cells treated with NC-ASO, s-ASO-g4, s-ASO-gl 1 and s-ASO-gl2 for 3days. (N=3, two-sided unpaired student’s t test; p-values - ASO-NC versus ASO-g4: 0.032, ns: non-significant). (d) Level of p-EZH2 / EZH2, H3K27me3 / H3 and GAPDH proteins in steric ASOs (0.5 pM) and EZH2 inhibitor (Tazemetostat) (0.5pM) treated cell lines (KMS11 and BTZ-R 8226). ASO-NC and DMSO are used as negative control for s-ASO and EZH2 inhibitor treatment respectively (N=3 biological replicates), (e) The percentage (mean ± SEM) of annexin+ cells and annexin- cells post treatment with steric ASOs in BTZ-R 8226 cells (N=4, p values determined by two-sided multiple t-test; p-values - NC-ASO: 0.0001, s-ASO-g4: 0.0001, s-ASO-gll: 0.001, s-ASO-gl2: 0.001). (f) Proliferation rate (mean ± SEM) of BTZ-R 8226 cells treated with NC-ASO and steric ASOs till day 4 (N=3, two-way ANOVA; p-values - NC Vs s-ASO-g4: non-significant, NC Vs s-ASO-gll: 0.005 and NC Vs s-ASO-gl2: 0.005). (g) Drug sensitivity IC50 survival curve (mean ± SEM) for steric ASOs and EZH2i (Tazemetostat) treated KMS11 cells in response to BTZ treatment for 24h and Len treatment for 4 days respectively (N=3, two-way ANOVA, p-values marked in the figure), (h) Drug sensitivity IC50 survival curve (mean ±SEM) for steric ASOs and EZH2i (T zemetostat) treated BTZ-R 8226 cells in response to BTZ treatment for 24h and Len-R KMS11 cells in response to Len treatment for 4 days respectively (N=3, two-way ANOVA; p-values - BTZ-R / +ASO-gll2 versus BTZ-R / EZH2i: 0.045, LenR / +ASO versus LenR / EZH2i: non-significant).

[0033] Figure 14. PLUM expression level regulates the activation of UPR pathway, (a) Enriched biological processes among uprcgulatcd DEGs upon PLUM knockdown in KMS11 cell line, (b) Enriched biological processes among downregulated DEGs upon PLUM knockdown in KMS 11 cell line, (c) Expression level (mean ± SEM) of UPR target genes (EDEM. CHOP, GRP94, ATF4 and Bip) in NF-KB+ and NF-KB- MMCLs. Fold changes have been normalised to MM.1. S sample (N=3, two-sided unpaired student’s t test: *: p value for mutant MMCLs versus XG-7, #: p value for mutant MMCLs versus H929; * / # p<0.05, ** / ## p<0.005, *** / ### p<0.0005, ns-non-significant; individual p-values provided in the source data file), (d) Expression level (mean ± SEM) of ATF6a target genes (Bip, HERPUDl, GRP94 and PDIA4) in MP LUM knock down and PLUM overexpressed MMCLs (KMS 11 and LP1) compared to sh-scramble and vector control respectively (N=3, two-sided unpaired student’s t test; p-values provided in the figure), (e) Level of UPR master regulators (p-IRElot, IREla, p-eIF2a, eIF2a and ATF6 a) in NC-ASO, sASO-g4, sASO-gll and sASO-gl2 treated KMS11 cells. (N=3 biological replicates), (f) Expression level of UPR master regulators (IRE1 a, eTF2a and ATF6a) in sh-TREI a, sh-eIF2a and sh-AFT6a KD PLUM OE KMS 11 cells, (g) Proliferative rate (mean ± SEM) of sh-eIF2a and sh-AFT6a KD in PLUM OE background KMS11 cells. (N=3; two-way ANOVA; VC versus PLUM OE: 0.0005, PLUM-OE versus shl-eIF2a: 0.016, PLUM-QE versus sh2-eIF2a: 0.0014, PLUM-QE versus shl-ATF6a: 0.0003, PLUM-QE versus sh2-ATF6a: 0.001). (h) Drag sensitivity IC50 curve (mean ± SEM) for sh-eIF2a KD and sh-ATF6a KD in PLUM OE background KMS 11 cells compared to vector control and scramble RNA in response to BTZ treatment for 24h. (N=2 biological replicates), (i) Expression level of IREla in BTZ-R 8226 and Len-R KMS 11 cell lines post shRNA mediated knockdown of IREla. (N=2 biological replicates).

[0034] Figure 15. PLUM-EZU2 interaction regulates H3K27 methylation marks globally, (a) Scatter plot highlighting significant loss of H3K27me3 at transcription start sites and associated genes upregulated upon PLUM KD in KMS 11 cells (adj. p-value <= 0.05; NS: non-significant). Genes relevant to enriched biological processes presented are indicated. (b,c) ChIP qPCR validation for FOXO3 and ZFP36 TSS in VC and EE-PLUM overexpressed KMS11 cells (N=3, mean ± SEM is plotted, two-sided unpaired student’s t test; p-values -F0X03 1: 0.04, F0X03 2: 0.009, ZFP36 1 0.05, ZFP30 2 0.004). (d) Level of FOXO3 and ZFP36 proteins in PLUM KD cells compared tosh-scramble and PLUM-VE, / Z / jW-AExon 1, PZ( / A -AExon7 overexpressed cells compared to VC (N=3 biological replicates). (e,f) ChIP qPCR validation for FOXO3 and ZFP36 TSS in sh-scramble and s\vl-PLU knock-down LP1 cells (N=3, mean ± SEM is plotted, two-sided unpaired student’s t test; p-values - FOXO3J: 0.027, FOXO3 2-. 0.05, ZFP 6 1 0.036, ZFP30 2-. 0.019). (g) Proliferative rate (mean ± SEM) of sh-scramble and sh-FOXO3 knock-down KMS11 cells at time point of 0, 2 and 4 days (N=3, two-way ANOVA done; p-values - scramble versus shl-FOXO3: 0.002, scramble versus sh2-? OX03: non-significant. (h) Proliferative rate (mean ± SEM) of sh-scramble and sh-ZFP36 transduced KMS11 cells at time point of 0, 2 and 4 days (N=3, two-way ANOVA done; p-values - scramble versus shl-ZFP 36'. 0.0001, scramble versus s 2-ZFP36 0.009. (i) Drug sensitivity ICso survival curve (mean ± SEM) of sh-scramble and sh-FOXO3 KD KMS11 cells post 24 h of treatment with BTZ (N=3, two-way ANOVA; p-values - scramble versus shl-FOXO3: 0.0001, scramble versus sh2-FOXO3: 0.0001). (j) Drug sensitivity ICso survival curve (mean ± SEM) of sh-scramble and sh-ZFP36 KD KMS11 cells post 24 h of treatment with BTZ (N=3, two-way ANOVA; p-values - scramble versus shl-ZFP36: 0.0001, scramble versus sh2-ZFP36-. 0.0037).

[0035] Figure 16. Steric ASO targeted disruption of P / .t / Af-EZHl interaction abrogates the tumour growth and BTZ resistance of MM. (a) Picture showing the PLUM overexpressed KMS11 tumor xenografts under different treatment groups PLUM OE + DMSO + NC-ASO, n=6; PLU OE + s-ASO-gl2, n=6; PLUM OE + BTZ, n=6; PLUM OE + s-ASO-gl2 + BTZ, n=6) at Day 28. (b) Average tumor volume for PLUM overexpressed KMS11 xenografts under different treatment groups {PLUM OE + DMSO + NC-ASO, n=6; PLUM OE + s-ASO-gl2, n=6; PLUM OE + BTZ, n=6; P UM OE + s-ASO-gl2 + BTZ, n=6) at Day 28. (N=6, mean ± SEM is plotted, two-sided unpaired student’s t test; p-values -NC+DMSO versus s-ASO-gl2: 0.0001, NC+DMSO versus BTZ: 0.0001, NC+DMSO versus BTZ+s-ASO-gl2: 0.0001, s-ASO-gl2 versus BTZ: non-sigmficant, s-ASO-gl2 versus BTZ+s-ASO-gl2: 0.0076, BTZ versus BTZ+s-ASO-gl2: 0.0002).

[0036] Detailed description

[0037] The specification teaches a method of treating a cancer comprising administering a pharmaceutically effective amount of a nucleic acid inhibitor of a long non-cording RNA (IncRNA), LINC02362 or PLUM. Specifically, the cancer is a blood cancer, more specifically, multiple myeloma (MM).

[0038] The present invention is predicated on the understanding that dysregulation of oncogenicpathways was believed to contribute to cancer chemoresistance, in particular MM. The inventors have identified that the non-canonical Nuclear Factor kappa-light-chain-enhancer of activated B cells (ncNF-KB) signaling pathway plays a role in reprogramming of the myeloma epigenome, which contributes to the chemoresistance and disease progression of multiple myeloma (MM). Furthermore, it was also believed that the deregulation of the unfolded protein response (UPR) pathway is causally linked to the poor clinical outcome of MM. In particular, a NF-KB / p52 regulated long non-coding RNA (IncRNA), LINC02362, was found to be overexpressed in NF-KB mutant, high-risk MM subtypes and VRd refractory patients. In this specification, the LINC02362 was also termed as PLUM (PRC2 associated LncRNA regulating UPR in MM). PLUM was found to interact with EZH2, the enzymatic subunit of PRC2 core, which mediates the PRC2 complex formation, and contributes to the chemoresistance of MM.

[0039] In this invention, the inventors have designed a steric antisense oligonucleotide (ASO) that is capable of recognizing nucleic acid sequences of PLUM. The steric ASO may then bind io PLUM, which may cause the PLUM-UZH2 interaction to be inhibited, and the steric ASO may further re-sensitize the multiple myeloma cells to drug treatment or chemotherapy. The inventors have also found that the designed steric ASOs targeting PLUM-EZM2. interaction showed similar effect with that of EZH2 inhibitor (tazemetostat) in the destabilization of EZH2 activity and abrogation of chemoresistance, supporting the possible use of PLUM as an alternative target to overcome the resistance mechanisms associated with known EZH2 catalytic inhibitors in MM. The designed steric ASOs may inhibit PLUM io diminish the tumorigenic effect of EZH2. This targeted approach may have higher specificity rather than global inhibition mechanism used by available EZH2 inhibitors, or inhibitory or degradative ASOs against PLUM and EZH2.

[0040] Advantageously, the steric ASOs designed by the inventors are part of both second and third generation mixed backbone ASO modification (mixmer) utilizing a combination of modified nucleotides including phosphorothioate (PS) linkages between nucleic acid residues and 2’-O-Methoxyethyl / locked nucleic acid at adenosine residue (2’M0E-LNAa+) or phosphorothioate (PS) linkages between nucleic acid residues and 2’MOE / locked nucleic acid residue at cytosine residue (2’M0E-LNAc+). Unlike 1st generation ASOs which are target site blockers (TSBs), the mixmer may not activate RNase H activity and may show improved nuclease resistance. This enhanced stability may lead to a longer half-life, whichis crucial for therapeutic efficacy Additionally, mixmer ASOs may be designed to act as steric blocks, that produce their biological effects by using steric hindrance, thereby preventing protein binding to target RNA. Such modifications may further enhance binding affinity for RNA as well as its stability. Furthermore, the use of mixmer ASOs may offer a balance between high binding affinity and flexibility of the ASOs, allowing for a wider range of applications. These mixmer ASOs may target specific region of RNA (such as non-coding RNAs) or may block the binding of RNA-binding proteins. Hence, this chemistry was utilised to design steric ASOs targeting / 77 / A7-EZH2 complex. The mixmer ASOs chemistry may improve nuclease stability and binding affinity, and may prevent the off-target or global effects of non-specific EZH2 inhibitors. The mixmer ASOs targeting PLUM may also further minimize off-target effects, reduce toxicity, and enhance affinity.

[0041] Use of mixmer ASOs may also provide an advantage over 1st generation ASO in mouse model in context of enhanced specificity and increased in-vivo efficacy. The alternating LNA and DNA nucleotides create a more likely binding interface with the target RNA, reducing the likelihood of off-target effects. The mixmer ASOs may provide better in vivo efficacy due to improved binding affinity and stability, allowing for more effective target RNA modulation. Unlike traditional ASOs, mixmer ASOs particularly with phosphorothioate (PS) backbones may increase plasma protein binding and enhance biodistribution, and may further enhance target tissue delivery and increase efficacy in vivo. These modifications may lower ASO toxicity and improve binding affinity to a target IncRNA, improve tissue uptake and chemical stability. Tn addition, the ASOs contain phosphorothioates (PS) modifications (i.e. substitution of one of the non-bridging oxygen atoms with a sulfur atom) within phosphodiester backbone of the RNA sequence. These PS modifications may increase resistance of the ASOs to nuclease degradation and enhance half-life. The steric ASOs may also be incapable of activating RNAse H due to the LNAa / LNAc modifications, hence, may bind to the PLUM sequence, which may be interacting with EZH2, and in turn induce the steric blocking of the PLUM-EZM2 interaction for re-sensitizing the cancer cells to drug therapy.

[0042] Disclosed herein is a method of treating a cancer in a subject in need thereof, comprising administering a pharmaceutically effective amount of a nucleic acid inhibitor of a long noncoding RNA (IncRNA), LINC02362, wherein the nucleic acid inhibitor is capable of inhibiting the interaction between LINC02362 and the Enhancer of Zeste Homolog 2(EZH2) polypeptide

[0043] Long non-coding RNA (IncRNA)

[0044] As used herein, the term “long non-coding RNA” or “IncRNA” refers to an RNA molecule comprising more than approximately 200 nucleotides in length that lacks a substantial protein-coding open reading frame and is not translated into a functional protein. A long non-coding RNA may be transcribed by RNA polymerase II, III, or another RNA polymerase, and may be capped, poly adenylated, spliced, or otherwise processed in a manner similar to messenger RNA. Long non-coding RNAs may be localized in the nucleus, cytoplasm, or other cellular compartments and may regulate gene expression at the transcriptional, post-transcriptional, translational, or epigenetic level. The IncRNA may promote chemoresistance in a cancer, resulting in a reduced sensitivity or non-responsiveness of the cancer to one or more drug treatments.

[0045] LINC02362 or PLUM

[0046] In one embodiment, the long non-coding RNA is a L1NC02362. As used herein, the terms " LINU02362" and “PLUM” are used interchangeably to refer to a gene that does not encode for any protein, and may be capable of regulating gene expression through its ability to bind RNA binding proteins (RBPs), and may modulate downstream signaling pathways. Without wanting to be bound by theory, the inventors found that LINC02362 may enhance EZH2 stability and activity towards chemoresistance of a cancer, such as a blood cancer. The LINC02362 may also bind to microRNA and act as a sponge, for regulating and / or modulating downstream signaling pathway. The LINC02362 may be expressed from a gene located at chromosome 4 of a human subject. The LINC02362 may be transcribed from the DNA template and may undergo post-transcriptional processing to form a mature LINC02362. The full length LINC02362 may comprise a nucleic acid sequence in SEQ ID NO: 19, or a complementary sequence thereof. The spliced LINC02362 may comprise a nucleic acid sequence in SEQ ID NO: 20, or a complementary sequence thereof.

[0047] In one embodiment, the nucleic acid inhibitor is capable of hybridizing and / or binding to a portion of a long non-coding RNA molecule, such as LINC02362. The nucleic acid inhibitor may comprise a substantially complementary sequence to the target IncRNA, such as SEQ ID NOs: 19-20, for hybridization, binding and inhibition.In some embodiments, the nucleic acid inhibitor comprises, encodes, or binds to a portion of a nucleic acid sequence having at least 70% sequence identity to a nucleic acid sequence in any one of SEQ ID NOs: 19-20, or a complementary sequence thereof.

[0048] In some embodiments, the nucleic acid inhibitor comprises, encodes, or binds to a portion of a nucleic acid sequence having at least 70% sequence identity to a nucleic acid sequence in SEQ ID NO: 21, or a complementary sequence thereof. In some embodiments, the nucleic acid inhibitor is capable of binding specifically to a nucleic acid sequence of SEQ ID NO: 21.

[0049] In some embodiments, the nucleic acid inhibitor is capable of inhibiting the interaction between a nucleic acid sequence having at least 70% sequence identity to a nucleic acid sequence in SEQ ID NO: 21 and the EZH2 polypeptide.

[0050] AAGGCAGCACAGGCCTTGCTGTTTGCCCATGCCCATGCGGTCAGCTCTCTTGG GTACCGTGGCATGCAGATGCAGACGCTCACCCAAGACACCCTGTAGTGCTGAT TACTGGCTGAAGACACTGAATATCTGATATAGTTTGGATGTTTGACCCCTCCAA ATCTCATGTTGAAACTAGATTCCCAGTGTTGGAGGTGGGGCCCGGTGGGAGGT GTTTGGATTGTGGGATTGGATCCCTTATGGCCATCTTGGTGCCATCCTTGTGGT AATGAGCAAGTTCTTTATCTACTAGTTCCTGAGCGAT (SEQ ID NO: 21)

[0051] Nucleic acid inhibitor

[0052] As used herein, the term “nucleic acid inhibitor” refers to a nucleic acid molecule capable of inhibiting or modulating the expression or function of a target gene or target nucleic acid by directly or indirectly interacting with the target gene or target nucleic acid in a sequencespecific or structure-specific manner. The mechanisms of inhibition may include but are not limited to hybridization-based blocking of transcription or translation, RNase El-mediated cleavage of a target RNA, inhibition or alteration of RNA splicing or processing, destabilization of a target nucleic acid, or steric hindrance of nucleic acid-protein interactions. In one embodiment, the nucleic acid inhibitor of LINC02362 is capable of inhibiting the interaction between PLUM and EZH2.

[0053] In some embodiments, the nucleic acid inhibitor is selected from the group consisting of a small interfering RNA (siRNA), an antisense nucleic acid (ASO), and a short hairpin RNA (shRNA).In some embodiments, the nucleic acid inhibitor comprises, encodes, or binds to a nucleic acid sequence of having at least 70% sequence identity to LINC02362, or a complementary sequence thereof.

[0054] In some embodiments, the nucleic acid inhibitor comprises, encodes, or binds to a nucleic acid sequence having at least 70% sequence identity to a nucleic acid sequence in any one of SEQ ID NOs: 2-4, 6-9, 11, 12, 14, or a complementary sequence thereof:

[0055] CTCCAGAAGGAGTTGAGAATG (SEQ ID NO: 2);

[0056] GAGTGAAAAATCCAAGGT (SEQ ID NO: 3);

[0057] GTATCAGCATCTATTTCA (SEQ ID NO: 4);

[0058] GCCATTATTTTAAGAAGACT (SEQ ID NO: 6);

[0059] CGTGTTGACCAGACTGAT (SEQ ID NO: 7);

[0060] AGATTATAGGTGTGAGCC (SEQ ID NO: 8);

[0061] GCTTCATGTACAGCCTGTAG (SEQ ID NO: 9);

[0062] CAGATAAGGCAGCACAGG (SEQ ID NO: 11);

[0063] CGGTGGGAGGTGTTTGGATTG (SEQ ID NO: 12);

[0064] CTAGCAGCATCATCCGCTCC (SEQ ID NO: 14).

[0065] In some embodiments, the nucleic acid inhibitor comprises, encodes, or binds to a nucleic acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to a nucleic acid sequence in any one of SEQ ID NOs: 2-4, 6-9, 11, 12, 14, or a complementary sequence thereof. In one embodiment, the nucleic acid inhibitor is capable of hybridizing and / or binding to a nucleic acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to a nucleic acid sequence in any one of SEQ ID NOs: 11-12, of a complementary sequence thereof. In another embodiment, the nucleic acid inhibitor is capable of hybridizing and / or binding to a nucleic acid sequence having 100% sequence identity to a nucleic acid sequence in any one of SEQ ID NOs: 11-12, or a complementary sequence thereof

[0066] In some embodiments, the nucleic acid inhibitor is a nucleic acid molecule comprising at least 70% sequence identity to any one of SEQ ID NOs: 15-16, or a complementary sequence thereof:

[0067] GUCUAUUCCGUCGUGUCC (SEQ ID NO: 15);GCCACCCUCCACAAACCUAAC (SEQ TD NO: 16).

[0068] In one embodiment, the nucleic acid inhibitor is a nucleic acid molecule comprising about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 99 %, or about 100% sequence identity to any one of SEQ ID NOs: 15-16, or a complementary sequence thereof.

[0069] Steric antisense nucleic acid

[0070] In some embodiments, the nucleic acid inhibitor is a steric antisense nucleic acid or steric oligonucleotide (“s-ASO”).

[0071] The term “nucleic acid” refers to a deoxyribonucleotide or ribonucleotide polymer in either single- or double-stranded form, and unless otherwise limited, encompasses known analogues of natural nucleotides that hybridize to nucleic acids in a manner similar to naturally occurring nucleotides. Such nucleic acid sequences include, for example, but are not limited to, nucleic acid sequence that act as transcriptional repressors, antisense molecules, ribozymes, small inhibitory nucleic acid sequences, for example, but not limited to, RNAi, shRNAi, siRNA, microRNAi (mRNAi), antisense oligonucleotides etc.

[0072] As used herein, the term “nucleic acid”, and equivalent terms such as “polynucleotide”, refer to a polymeric form of nucleotides of any length, such as ribonucleotides, deoxyribonucleotides or peptide nucleic acids (PNAs), that comprise purine and pyrimidine bases, or other natural, chemically or biochemically modified, non-natural, or derivatized nucleotide bases. The nucleic acid may be double stranded or single stranded. References to single stranded nucleic acids include references to the sense or antisense strands. The backbone of the polynucleotide can comprise sugars and phosphate groups, as may typically be found in RNA or DNA, or modified or substituted sugar or phosphate groups. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. The sequence of nucleotides may be interrupted by non-nucleotide components. The terms nucleoside, nucleotide, deoxynucleoside and deoxynucleotide generally include complements, fragments and variants of the nucleoside, nucleotide, deoxynucleoside and deoxynucleotide, or analogs thereof.

[0073] The term “nucleotide” refers to a ribonucleotide or a deoxyribonucleotide or modified form thereof, as well as an analogue thereof. Nucleotides include species that comprise purines,e g., adenine, hypoxanthine, guanine, and their derivatives and analogues, as well as pyrimidines, e.g., cytosine, uracil, thymine, and their derivatives and analogues.

[0074] An “oligonucleotide” as used herein is a single stranded molecule which may be used in hybridization or amplification technologies. In general, an oligonucleotide may be any integer from about 15 to about 100 nucleotides in length, but may also be of greater length.

[0075] The term “nucleotide” is also meant to include what are known in the art as universal bases. By way of example, universal bases include but are not limited to 3 -nitropyrrole, 5-nitroindole, or nebularine. The term “nucleotide” is also meant to include the N3’ to P5’ phosphoramidate, resulting from the substitution of a ribosyl 3 ’ oxygen with an amine group. Further, the term nucleotide also includes those species that have a detectable label, such as for example a radioactive or fluorescent moiety, or mass label attached to the nucleotide.

[0076] Modified bases refer to nucleotide bases such as, for example, adenine, guanine, cytosine, thymine, uracil, xanthine, inosine, and queuosine that have been modified by the replacement or addition of one or more atoms or groups. Some examples of types of modifications that can comprise nucleotides that are modified with respect to the base moieties include but are not limited to, alkylated, halogenated, thiolated, aminated, amidated, or acetylated bases, individually or in combination. More specific examples include, for example, 5-propynyluridine, 5-propynylcytidine, 6-methyladenine, 6-methylguanine, N, N, -dimethyladenine, 2-propyladenine, 2-propylguanine, 2-aminoadenine, 1 -methylinosine, 3-methyluridine, 5 -methyl cytidine, 5-methyluridine and other nucleotides having a modification at the 5 position, 5-(2-amino)propyl uridine, 5-halocytidine, 5-halouridine, 4-acetylcytidine, 1 -methyladenosine, 2-methyl adenosine, 3 -methylcytidine, 6-methyluridine, 2-methylguanosine, 7-methylguanosine, 2,2-dimethylguanosine, 5-methylaminoethyluridine, 5 -methyloxyuridine, deazanucleotides such as 7-deaza-adenosine, 6-azouridine, 6-azocytidine, 6-azothymidine, 5-methyl-2-thiouridine, other thio bases such as 2-thiouridine and 4-thiouridine and 2-thiocytidine, di hydrouridine, pseudouridine, queuosine, archaeosine, naphthyl and substituted naphthyl groups, any O- and N-alkylated purines and pyrimidines such as N6-methyladenosine, 5-methylcarbonylmethyluridine, uridine 5-oxyacetic acid, pyridine-4-one, pyridine-2-one, phenyl and modified phenyl groups such as aminophenol or 2,4,6-trimethoxy benzene, modified cytosines that act as G-clamp nucleotides, 8-substituted adenines and guanines, 5-substituted uracils and thymines, azapyrimidines, carboxyhydroxyalkyl nucleotides, carboxyalkylaminoalkyl nucleotides, and alkylcarbonylalkylated nucleotides. Modified nucleotides also include those nucleotides that are modified with respect to the sugar moiety, as well as nucleotides having sugars or analogs thereof that are not ribosyl. For example, the sugar moieties may be, or be based on, mannoses, arabinoses, glucopyranoses, galactopyranoses, 4’-thioribose, and other sugars, heterocycles, or carbocycles.

[0077] As used herein, the terms “antisense oligonucleotide”, “antisense nucleic acid” and “ASO”, are used interchangeably to refer to a single-stranded nucleic acid molecule comprising a sequence that is substantially complementary to at least a portion of a target nucleic acid sequence, such that the antisense nucleic acid is capable of sequence-specific hybridization to the target nucleic acid molecule under physiological conditions and may modulate the biological function of the target nucleic acid An antisense nucleic acid may inhibit, reduce, alter, or modulate a biological function of a target nucleic acid by any suitable mechanism, including but are not limited to, RNase H-mediated cleavage of the target nucleic acid, steric blocking of binding, translation, splicing, and / or processing of the target nucleic acid, or interference with nucleic acid transport, localization and / or stability. The antisense nucleic acid may comprise deoxyribonucleotides, ribonucleotides, or a combination thereof, and may comprise one or more chemically modified nucleotides, nucleotide analogues, backbone modifications, or conjugated moieties, provided that the antisense nucleic acid retains the ability to hybridize to the target RNA in a sequence-specific manner.

[0078] An antisense oligonucleotide (ASO) may comprise one or more different classes of chemical modifications, including first-generation, second-generation, and / or third-generation modifications. First-generation antisense oligonucleotides primarily comprise phosphorothioate (PS) inter-nucleotide linkages, in which one or more natural phosphodiester linkages between adjacent nucleic acid residues are wholly or partially replaced with phosphorothioate (PS) linkages. The presence of PS linkages may increase nuclease resistance as compared with an unmodified nucleic acid, may retain the ability to induce RNase H-mediated degradation of a target nucleic acid molecule, and may facilitate systemic delivery due to enhanced plasma protein binding. Second-generation antisense oligonucleotides may comprise one or more 2’-sugar-modified nucleic acid residues. Such modifications include, but are not limited to, 2’-O-methyl (2’0Me) modifications, 2’-O-methoxyethyl (2’MOE) modifications, and phosphorothioate backbone linkages. Incertain embodiments, a second-generation ASO adopts a gapmer architecture, wherein a central region comprising deoxyribonucleotides (a “gap region”) capable of supporting RNase H activity is flanked at the 5’ and 3’ ends by regions comprising modified nucleic acid residues (collectively, “wing regions”). Second-generation ASOs may be characterized by enhanced binding affinity for a target nucleic acid, improved nuclease resistance, reduced toxicity relative to first-generation ASOs, and retention of an RNase H-dependent mechanism of action. Third-generation antisense oligonucleotides may comprise conformationally constrained or structurally modified nucleic acid analogues, which may further enhance binding affinity, specificity, and pharmacological properties under physiological conditions. Third-generation modifications include, but are not limited to, locked nucleic acids (LNA), constrained ethyl (cEt) nucleic acids, bridged nucleic acids (BNA), phosphorodiamidate morpholino oligomers (PMO), peptide nucleic acids (PNA), and other conformationally constrained nucleic acid analogues. Third-generation ASOs may adopt a mixmer architecture. Third-generation ASOs may modulate a target nucleic acid through RNase H-dependent mechanisms, RNase H-independent mechanisms, steric blocking of nucleic acid function, or combinations thereof.

[0079] As used herein, the term “mixmer” refers to an antisense oligonucleotide comprising a sequence that includes two or more different types of nucleotides or nucleotide analogues interspersed along the length of the oligonucleotide, wherein the nucleotide types may differ in their sugar moiety, base modification, backbone chemistry, or a combination thereof. In a mixmer, modified nucleotides and unmodified nucleotides, or different classes of modified nucleotides, are distributed within the same strand rather than being segregated into discrete contiguous regions.

[0080] In some embodiments, the nucleic acid inhibitor consists of about 10 to about 40 nucleotides in length. The nucleic acid inhibitor may consist of about 10 to 30, about 15 to 25, or about 18 to 23 nucleotides in length. The nucleic acid inhibitor may consist of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides in length.

[0081] In some embodiments, the nucleic acid inhibitor comprises at least a modified nucleic acid residue selected from a group comprising phosphorothioate (PS) linkage modification, sugar moiety modification, locked nucleic acid (LNA), or a combination thereof. In oneembodiment, the sugar moiety modification is a 2’-O-Methoxyethyl (2’MOE) modification

[0082] In some embodiments, the nucleic acid inhibitor comprises at least 1 phosphorothioate (PS) linkage or PS bond between adjacent nucleic acid residues, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more PS linkages. In one embodiment, all the bonds between adjacent nucleic acid residues are phosphorothioate (PS) linkages.

[0083] In some embodiments, the antisense nucleic acid is a steric antisense nucleic acid or steric antisense oligonucleotide (“s-ASO”). The steric antisense nucleic acid may comprise a mixture of second-generation and third-generation modifications, such as wholly or partially phosphorothioate (PS) linkages or backbone modification, modified sugar, and locked nucleic acid. In one embodiment, the steric antisense oligonucleotide comprises wholly PS linkages, 2’-O-Methoxyethyl (2’MOE) modified nucleic acid and locked nucleic acid at adenosine residue (LNAa). In another embodiment, the steric antisense oligonucleotide comprises wholly PS linkages, 2’-O-Methoxyethyl (2’MOE) modified nucleic acid and locked nucleic acid at cytosine residue (LNAc).

[0084] The term “complementary” refers to the base pairing between nucleotides or nucleic acids, such as, for instance, between the two strands of a double stranded DNA molecule or between an oligonucleotide primer and a primer binding site on a single stranded nucleic acid to be sequenced or amplified. Complementary nucleotides are, generally, A and T (or A and U), or C and G. Two single stranded RNA or DNA molecules are said to be complementary when the nucleotides of one strand, optimally aligned and compared and with appropriate nucleotide insertions or deletions, pair with at least about 80% of the nucleotides of the other strand, usually at least about 90% to 95%, and more preferably from about 98 to 100% of the nucleotides of the other strand. Alternatively, complementarity exists when an RNA or DNA strand will hybridize under selective hybridization conditions to its complement. Typically, selective hybridization will occur when there is at least about 65% complementarity over a stretch of at least 14 to 25 nucleotides, preferably at least about 75%, and more preferably at least about 90% complementarity.

[0085] As used herein, the term “encode” refers broadly to any process whereby the information in a polymeric macromolecule is used to direct the production of a second molecule that is different from the first. The second molecule may have a chemical structure that is differentfrom the chemical nature of the first molecule

[0086] As used herein, the term "hybridization" or "hybridizes" refers to the process in which two single-stranded polynucleotides bind non-covalently to form a stable double-stranded polynucleotide. The term "hybridization" may also refer to triple-stranded hybridization. The resulting (usually) double-stranded polynucleotide is a "hybrid" The proportion of the population of polynucleotides that forms stable hybrids is referred to herein as the "degree of hybridization".

[0087] The term “at least 70% sequence identity” may refer to at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity.

[0088] The term “sequence identity” as used herein refers to the extent that sequences are identical on a nucleotide-by-nucleotide basis or an amino acid-by-amino acid basis over a window of comparison. Thus, a “percentage of sequence identity” is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, 1) or the identical amino acid residue (e.g., Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gin, Cys and Met) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. For the purposes of the present invention, “sequence identity” will be understood to mean the “match percentage” calculated by the DNASIS computer program (Version 2.5 for windows; available from Hitachi Software engineering Co., Ltd., South San Francisco, California, USA) using standard defaults as used in the reference manual accompanying the software.

[0089] Terms used to describe sequence relationships between two or more polynucleotides or polypeptides include “reference sequence,” “comparison window”, “sequence identity,” “percentage of sequence identity” and “substantial identity”. A “reference sequence” is at least 12 but frequently 15 to 18 and often at least 25 monomer units, inclusive of nucleotides and amino acid residues, in length. Because two polynucleotides may each comprise (1) a sequence (i.e., only a portion of the complete polynucleotide sequence) that is similar between the two polynucleotides, and (2) a sequence that is divergent between the twopolynucleotides, sequence comparisons between two (or more) polynucleotides are typically performed by comparing sequences of the two polynucleotides over a “comparison window” to identify and compare local regions of sequence similarity. A “comparison window” refers to a conceptual segment of at least 6 contiguous positions, usually about 50 to about 100, more usually about 100 to about 150 in which a sequence is compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. The comparison window may comprise additions or deletions (i.e., gaps) of about 20% or less as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Optimal alignment of sequences for aligning a comparison window may be conducted by computerized implementations of algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Drive Madison, WI, USA) or by inspection and the best alignment (i.e., resulting in the highest percentage homology over the comparison window) generated by any of the various methods selected. Reference also may be made to the BLAST family of programs as for example disclosed by Altschul et al., 1997, Nucl. Acids Res.25:3389. A detailed discussion of sequence analysis can be found in Unit 19.3 of Ausubel et al., “Current Protocols in Molecular Biology”, John Wiley & Sons Inc, 1994-1998, Chapter 15.

[0090] In some embodiments, the nucleic acid inhibitor is a nucleic acid molecule comprising at least 70% sequence identity to any one of SEQ ID NOs: 17-18, or a complementary sequence thereof:

[0091] 5’-mG*mT*C*mT*mA*mT*mT*C*C*mG*mT*C*mG*mT*mG*mT*C*C-3’

[0092] (SEQ ID NO: 17);

[0093] 5’-mG*mC*mC*mA*mC*mC*mC*mT*mC*mC*mA*mC*mA*mA*mA*mC*mC*mT* mA*mA*mC-3’ (SEQ ID NO: 18), wherein:

[0094] m = 2’-O-Methoxyethyl (2’MOE) modification;

[0095] * = phosphorothioate (PS) linkage; and

[0096] underline = locked nucleic acid.

[0097] In some embodiments, the steric antisense nucleic acid inhibits and / or disrupts the IncRNA-EZH2 interaction. In another embodiment, the steric antisense nucleic acid inhibits and / or disrupts the PLUM-EZH2 interaction. The steric antisense nucleic acid may inhibit and / ordisrupt a target nucleic acid-protein interaction via steric hindrance, and may not cause degradation of the target nucleic acid. This may further inhibit the activity of the EZH2 protein.

[0098] Pharmaceutically acceptable carrier

[0099] In some embodiments, the nucleic acid inhibitor is provided in a pharmaceutically acceptable carrier.

[0100] As used herein, the term “pharmaceutically acceptable carrier” refers to a pharmaceutical vehicle comprising a material that is not biologically or otherwise undesirable, i.e., the material may be administered to a subject along with the selected active agent without causing any or a substantial adverse reaction. Carriers may include excipients and other additives such as diluents, detergents, colouring agents, wetting or emulsifying agents, pH buffering agents, preservatives, and the like.

[0101] Representative pharmaceutically acceptable carriers include any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drugs, drug stabilizers, gels, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, such like materials and combinations thereof, as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed Mack Printing Company, 1990, pp 1289-1329, incorporated herein by reference). Except insofar as any conventional carrier is incompatible with the active ingredient(s), its use in the pharmaceutical compositions is contemplated.

[0102] The pharmaceutical compositions may be in a variety of forms. These include, for example, liquid, semi-solid and solid dosage forms, such as liquid solutions (e g., injectable and infusible solutions), dispersions or suspensions, liposomes and suppositories. The preferred form depends on the intended mode of administration and therapeutic application. Suitable pharmaceutical compositions may be administered intratumorally, intravenously, subcutaneously or intramuscularly. In some embodiments, the compositions are in the form of injectable or infusible solutions. In some embodiments, the administration is parenteral (e.g., intravenous, subcutaneous, intraperitoneal, intramuscular, intranasal, topical or transdermal). In another embodiment, the administration is intratumoralAdministering

[0103] The term “administering” refers to contacting, applying, injecting, transfusing or providing a nucleic acid inhibitor as referred to herein to a subject.

[0104] Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic / aqueous solutions, emulsions or suspensions, including saline and buffered media. In the subject invention, pharmaceutically acceptable carriers include, but are not limited to, 0.01-0. IM and preferably 0.05M phosphate buffer or 0.8% saline. Other common parenteral vehicles include sodium phosphate solutions, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers, such as those based on Ringer's dextrose, and the like. Preservatives and other additives can also be present such as for example, antimicrobials, antioxidants, chelating agents, and inert gases and the like.

[0105] The nucleic acid inhibitor according to the present invention is preferably administered parenterally. More preferably, the nucleic acid inhibitor is to be administered intravenously, intramuscularly, subcutaneously, intra-arterially, intraocularly, intravitreally or intraosseously. Even more preferably, the nucleic acid inhibitor is to be administered intravenously, intramuscularly, subcutaneously or intra-arterially. Still more preferably, the nucleic acid inhibitor is to be administered intravenously or intramuscularly.

[0106] Chemoresistance

[0107] In some embodiments, the subject is found to be chemoresistant to a drug therapy.

[0108] In one embodiment, the drug therapy comprises Velcade® (bortezomib) with Revlimid® (lenalidomide) and dexamethasone (collectively VRd regime). As used herein, the terms “chemoresistance” or “chemoresistant” refer to the ability of cancer cells to withstand or evade the cytotoxic effects of therapeutic agents such as chemotherapeutic agents, resulting in reduced treatment efficacy or complete treatment failure. Chemoresistance may be intrinsic, where cancer cells are inherently non-responsive to therapy, or acquired, where resistance develops following initial sensitivity to treatment. Mechanisms contributing tochemoresistance may include altered drug uptake or efflux, enhanced DNA damage repair, evasion of apoptosis, activation of pro-survival signaling pathways, epigenetic reprogramming, and interactions with the tumor microenvironment. Additionally, transcriptional and epigenetic plasticity may enable cancer cells to adapt to therapeutic stress, promoting survival and disease progression.

[0109] EZH2

[0110] In some embodiments, the subject is found to be non-responsive to an EZH2 inhibitor therapy.

[0111] Enhancer of Zeste Homolog 2 (EZH2) is a histone lysine methyltransferase and the catalytic subunit of the Polycomb Repressive Complex 2 (PRC2), an epigenetic regulatory complex involved in transcriptional repression. EZH2 may mediate gene silencing primarily through trimethylation of histone H3 at lysine 27 (H3K27me3), a chromatin mark associated with suppression of genes regulating cellular differentiation, development, and cell-cycle control. PRC2 typically comprises EZH2 together with cofactors such as EED and SUZ12, which are required for structural stability and enzymatic activity. Beyond its canonical role, EZH2 may also exert non-canonical, PRC2-independent functions, including regulation of non-histone substrates and, in certain contexts, activation of gene expression. In an EZH2 inhibitor therapy, the inhibitors may bind to the EZH2 enzyme, reducing H3K27me3 levels, and thus may allow re-activation or re-expression of tumor-suppressor genes. Examples of EZH2 inhibitor therapy include Tazemotostat, Valemetostat, GSK126, Tulmimotostat, CPI-1205, and PF-06821497.

[0112] In some embodiments, the EZH2 polypeptide comprises an amino acid sequence of at least 70% sequence identity to SEQ ID NO: 78. For example, the EZH2 polypeptide may comprise an amino acid sequence of about 70%, about 80%, about 90%, about 95%, about 99%, or about 100% sequence identity to SEQ ID NO: 78.

[0113] Cancer

[0114] The terms “cancer” and “cancerous” refer to or describe the physiological condition in mammals that is typically characterized in part by unregulated cell growth. As used herein, the term “cancer” refers to non-metastatic and metastatic cancers, including early stage and late stage cancers. The term “precancerous” refers to a condition or a growth that typicallyprecedes or develops into a cancer. By “non-metastatic” is meant a cancer that is benign or that remains at the primary site and has not penetrated into the lymphatic or blood vessel system or to tissues other than the primary site. Generally, a non-metastatic cancer is any cancer that is a Stage 0, 1, or II cancer, and occasionally a Stage III cancer. By “early stage cancer” is meant a cancer that is not invasive or metastatic or is classified as a Stage 0, 1, or II cancer. The term “late stage cancer” generally refers to a Stage III or Stage IV cancer, but can also refer to a Stage II cancer or a substage of a Stage II cancer. One skilled in the art will appreciate that the classification of a Stage II cancer as either an early stage cancer or a late stage cancer depends on the particular type of cancer. Illustrative examples of cancer include, but are not limited to, breast cancer, prostate cancer, ovarian cancer, cervical cancer, pancreatic cancer, colorectal cancer, lung cancer, hepatocellular cancer, gastric cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, brain cancer, non-small cell lung cancer, squamous cell cancer of the head and neck, endometrial cancer, multiple myeloma, rectal cancer, and esophageal cancer. In some embodiments, the cancer is a blood cancer or a solid tumor.

[0115] In some embodiments, the blood cancer is a myeloma or lymphoma.

[0116] Multiple myeloma (also referred to as myeloma) is a hematologic malignancy characterized by the clonal proliferation of malignant plasma cells within the bone marrow Plasma cells are terminally differentiated B lymphocytes responsible for the production of immunoglobulins In myeloma, malignant plasma cells accumulate abnormally and produce excessive amounts of monoclonal immunoglobulins or immunoglobulin fragments, commonly referred to as M-proteins or paraproteins. Myeloma typically arises from precursor conditions such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma, and progresses through a multistep process involving genetic, epigenetic, and microenvironmental alterations.

[0117] Examples of blood cancers include, but are not limited to, leukemias, lymphomas, plasma cell disorders, myelodysplastic syndromes, and myeloproliferative neoplasms. Leukemias may be acute or chronic and include, for example, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, and chronic myeloid leukemia. Lymphomas encompass both Hodgkin and non-Hodgkin lymphomas, including B-cell and T-cell lymphomas such as diffuse large B-cell lymphoma, follicular lymphoma, andperipheral T-cell lymphoma Plasma cell disorders include multiple myeloma, and plasmacytoma. Myelodysplastic syndromes and myeloproliferative neoplasms include conditions characterized by abnormal proliferation or differentiation of hematopoietic cells, such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis. In one embodiment, the cancer is a multiple myeloma.

[0118] In some embodiments, the cancer is a cancer that overexpresses EZH2 and / or LINC02362 as compared to a reference In some embodiments, the cancer is a cancer that is characterised by an increased expression and / or activity of EZH2 and / or LINC02362 as compared to a reference. For example, the cancer may be a cancer that is associated with non-canonical NF-KB mutation. The mutation may be an activating mutation or a gain-of-function mutation, which may lead to an increased expression or activity of NF- B. The mutation may be present in a NF-KB component, such as TRAF2, TRAF3, cIAPl / 2, CYLD, and NIK The mutation may be present at the genetic level and / or protein level.

[0119] In some embodiments, the subject may have a disease associated with an increased expression and / or activity of EZH2, LINC02362, and / or NF-KB. For example, the disease may be an inflammatory disease.

[0120] The “reference” as referred to herein may be one or more non-cancerous samples taken from the same subject or one or more non-cancerous samples taken from another subject (e.g. a healthy subject who does not suffer from cancer). The reference may also be a predetermined value or an average value. In some embodiments, the method as defined herein comprises the step of comparing the level of one or more biomarkers, such as EZH2 and / or LINC02362 level, to a reference.

[0121] As used herein, the term "subject" includes any human or non-human animal. In one embodiment, the subject is a human. The term "non-human animal" includes all vertebrates, e g., mammals and non-mammals, such as non-human primates, sheep, dog, cow, chickens, amphibians, reptiles, etc.

[0122] As used herein, the terms “treating”, “treatment” and the like refer to partially or completely alleviating, ameliorating, improving, relieving, reducing, delaying onset of, inhibiting progression of, reducing severity of, and / or reducing incidence of one or more symptoms orfeatures of a particular infection, disease, disorder, and / or condition for at least a period of time. It is also to be understood that terms “treating”, “treatment” and the like do not imply that the condition, or a symptom thereof, is permanently relieved, reduced, alleviated, ameliorated or otherwise inhibited and therefore also encompasses the temporary relief, reduction, alleviation, amelioration or otherwise inhibition of the condition, or of a symptom thereof.

[0123] The terms “patient”, “subject”, “host” or “individual” are used interchangeably herein, refer to any subject, particularly a vertebrate subject, and even more particularly a mammalian subject, for whom therapy or prophylaxis is desired. Suitable vertebrate animals that fall within the scope of the invention include, but are not restricted to, any member of the subphylum Chordata including primates (e.g., humans, monkeys and apes, and includes species of monkeys such from the genus Macaca (e.g., cynomologus monkeys such as Macaca fascicularis, and / or rhesus monkeys (Macaca mulatto) and baboon (Papio ursimis), as well as marmosets (species from the genus Callithrix), squirrel monkeys (species from the genus Saimiri) and tamarins (species from the genus Saguinus), as well as species of apes such as chimpanzees (Pan troglodytes)), rodents (e.g., mice rats, guinea pigs), lagomorphs (e.g., rabbits, hares), bovines (e.g., cattle), ovines (e.g., sheep), caprines (e.g., goats), porcines (e.g., pigs), equines (e.g., horses), canines (e.g., dogs), felines (e.g., cats), avians (e g., chickens, turkeys, ducks, geese, companion birds such as canaries, budgerigars etc.), marine mammals (e.g., dolphins, whales), reptiles (snakes, frogs, lizards etc.), and fish.

[0124] Disclosed herein is a nucleic acid inhibitor of LINC02362, wherein the nucleic acid inhibitor of LINC02362 comprises, encodes, or binds to a nucleic acid sequence having at least 70% sequence identity to a nucleic acid sequence in any one of SEQ ID NOs: 19-20, or a complementary sequence thereof.

[0125] In some embodiments, the nucleic acid inhibitor of LINC02362 comprises, encodes, or binds to a nucleic acid sequence having at least 70% sequence identity to a nucleic acid sequence in any one of SEQ ID NOs: 2-4, 6-9, 11, 12, 14, or a complementary sequence thereof:

[0126] CTCCAGAAGGAGTTGAGAATG (SEQ ID NO: 2); GAGTGAAAAATCCAAGGT (SEQ ID NO: 3); GTATCAGCATCTATTTCA (SEQ ID NO: 4); GCCATTATTTTAAGAAGACT (SEQ ID NO: 6);CGTGTTGACCAGACTGAT (SEQ ID NO: 7);

[0127] AGATTATAGGTGTGAGCC (SEQ ID NO: 8); GCTTCATGTACAGCCTGTAG (SEQ ID NO: 9); CAGATAAGGCAGCACAGG (SEQ ID NO: 11); CGGTGGGAGGTGTTTGGATTG (SEQ ID NO: 12); CTAGCAGCATCATCCGCTCC (SEQ ID NO: 14).

[0128] In some embodiments, the nucleic acid inhibitor of LINC02362 comprises, encodes, or binds to a nucleic acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to a nucleic acid sequence in any one of SEQ ID NOs: 2-4, 6-9, 11, 12, 14, or a complementary sequence thereof. In one embodiment, the nucleic acid inhibitor of LINC02362 is capable of hybridizing and / or binding to a nucleic acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to a nucleic acid sequence in any one of SEQ ID NOs: 11-12, of a complementary sequence thereof. In another embodiment, the nucleic acid inhibitor of LINC02362 is capable of hybridizing and / or binding to a nucleic acid sequence having 100% sequence identity to a nucleic acid sequence in any one of SEQ ID NOs: 11-12, or a complementary sequence thereof.

[0129] In some embodiments, the nucleic acid inhibitor of LINC02362 is a nucleic acid molecule comprising at least 70% sequence identity to any one of SEQ ID NOs: 15-16, or a complementary sequence thereof:

[0130] GUCUAUUCCGUCGUGUCC (SEQ ID NO: 15); GCCACCCUCCACAAACCUAAC (SEQ ID NO: 16).

[0131] In one embodiment, the nucleic acid inhibitor of LINC02362 is a nucleic acid molecule comprising about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 99 %, or about 100% sequence identity to any one of SEQ ID NOs: 15-16, or a complementary sequence thereof.

[0132] In some embodiments, the nucleic acid inhibitor of LINC02362 consists of about 10 to about 40 nucleotides in length. The nucleic acid inhibitor may consist of about 10 to 30, about 15 to 25, about 16 to 24, about 17 to 22 or about 18 to 23 nucleotides in length. The nucleic acid inhibitor may consist of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26,27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides in length.

[0133] In some embodiments, the nucleic acid inhibitor of LINC02362 comprises at least a modified nucleic acid residue selected from a group comprising phosphorothioate (PS) linkage modification, sugar moiety modification, locked nucleic acid (LNA), or a combination thereof. In one embodiment, the sugar moiety modification is a 2’-O-Methoxyethyl (2’MOE) modification.

[0134] In some embodiments, the nucleic acid inhibitor of LINC02362 comprises at least 70% sequence identity to any one of SEQ ID NOs: 17-18, or a complementary sequence thereof:

[0135] 5’-mG*mT*C*mT*mA*mT*mT*C*C*mG*mT*C*mG*mT*mG*mT*C*C-3’

[0136] (SEQ ID NO: 17);

[0137] 5’-mG*mC*mC*mA*mC*mC*mC*mT*mC*mC*mA*mC*mA*mA*mA*mC* mC*mT*mA*mA*mC-3’ (SEQ ID NO: 18), wherein:

[0138] m = 2’-O-Methoxyethyl (2’MOE) modification;

[0139] * = phosphorothioate (PS) linkage; and

[0140] underline = locked nucleic acid.

[0141] Disclosed herein is a method of detecting a cancer with drug resistance in a subject, the method comprising: (a) detecting the level of expression of EZH2 and / or LINC02362 in a sample from the subject, wherein an increased expression of EZH2 and / or LINC02362 as compared to a reference indicates that the subject is likely to have the cancer with drug resistance; and (b) administering a pharmaceutically effective amount of a nucleic acid inhibitor of LINC02362 to the subject found likely to have the cancer with drug resistance.

[0142] The terms “detecting”, “determining”, “measuring”, “evaluating”, “assessing” and “assaying” are used interchangeably herein to refer to any form of measurement, and include determining if an element is present or not. These terms include both quantitative and / or qualitative determinations. Assessing may be relative or absolute. The method as defined herein may comprise measuring or visualising the levels of two or more polynucleotide or polypeptide analytes in a sample.As used herein, the term “increase” or “increased’ may refer to a statistically significant and measurable increase in the level of EZH2 and / or LINC02362, as compared to a reference. The increase may be, for example, an increase of at least about 1%, at least about 2%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90% or up to and including a 100% increase or any increase between 1 -100% as compared to a reference level. The increase may be from about 1-fold to about 10-fold, such as about 1-fold, about 1.5-fold, about 2-fold, about 3-fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, about 8-fold, about 9-fold, about 10-fold, or more.

[0143] The polynucleotide and / or polypeptide analytes and the corresponding level of expression or activity may be detected or measured using methods known in the art. Examples of the methods of detecting the analytes including but are not limited to Western blot, RT-qPCR, RNA-seq, transcriptome panels, enzyme-linked immunosorbent assay (ELISA), immunohistochemistry, immunocytochemistry, immunofluorescence, in situ hybridisation, tissue sectioning, multiplex immunoassays, flow cytometry, and mass spectrometry.

[0144] A sample can be a biological sample which refers to the fact that it is derived or obtained from a living organism. The organism can be in vivo (e.g. a whole organism) or can be in vitro (e g., cells or organs grown in culture) A "biological sample" also refers to a cell or population of cells or a quantity of tissue or fluid from a subject. Most often, a sample has been removed from a subject, but the term "biological sample" can also referto cells or tissue analyzed in vivo, i.e., without removal from the subject. Often, a "biological sample" will contain cells from a subject, but the term can also refer to non-cellular biological material, such as non-cellular fractions of blood, saliva, or urine. The biological sample may be from a resection, bronchoscopic biopsy, or core needle biopsy of a primary, secondary or metastatic tumor, or a cellblock from pleural fluid. In addition, fine needle aspirate biological samples are also useful. In one embodiment, a biological sample is blood and / or urine. Biological samples also include explants and primary and / or transformed cell cultures derived from patient tissues. A biological sample can be provided by removing a sample of cells from subject, but can also be accomplished by using previously isolated cells or cellular extracts (e g isolated by another person, at another time, and / or for another purpose).Archival tissues, such as those having treatment or outcome history may also be used. Biological samples include, but are not limited to, tissue biopsies, scrapes (e.g. buccal scrapes), whole blood, plasma, serum, urine, saliva, cell culture, or cerebrospinal fluid.

[0145] As used herein, the term “sample” includes tissues, cells, body fluids and isolates thereof etc., isolated from a subject, as well as tissues, cells and fluids etc. present within a subject (i.e. the sample is in vivo). Examples of samples include: whole blood, blood fluids (e.g. serum and plasm), lymph and cystic fluids, sputum, stool, tears, mucus, hair, skin, ascitic fluid, cystic fluid, urine, nipple exudates, nipple aspirates, sections of tissues such as biopsy and autopsy samples, frozen sections taken for histologic purposes, archival samples, explants and primary and / or transformed cell cultures derived from patient tissues etc.

[0146] The sample (such as a tissue or cell sample) may be fixed and permeabilized before hybridization with a pair of nucleic acid probe as defined herein, to retain the analytes in the cell and to permit the nucleic acid probes, bridge probes, etc to enter the sample The sample is optionally washed to remove materials not captured to one of the analytes. The sample can be washed after any of the various steps, for example, after hybridization of the nucleic acid probes to the analytes to remove unbound nucleic acid probes or after hybridization with the nucleic acid probes and bridge probes, before removing unbound nucleic acid probe and bridge probes.

[0147] Disclosed herein is a use of a nucleic acid inhibitor of LINC02362 in the manufacture of a medicament for treating a subject with a cancer.

[0148] Disclosed herein is a nucleic acid inhibitor of LINC02362, for use in the treatment of a cancer.

[0149] Disclosed herein is a pharmaceutical composition comprising a nucleic acid inhibitor of LINC02362 for use in the treatment of a cancer.

[0150] Disclosed herein is a use of a pharmaceutical composition comprising nucleic acid inhibitor of LINC02362 in the manufacture of a medicament for a cancer.As used herein, “and / or” refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations when interpreted in the alternative (or).

[0151] As used in this application, the singular form “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “an agent” includes a plurality of agents, including mixtures thereof.

[0152] Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising”, will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

[0153] The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.

[0154] Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications, which fall within the spirit and scope. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

[0155] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0156] Certain embodiments of the invention will now be described with reference to the following examples which are intended for the purpose of illustration only and are not intended to limit the scope of the generality hereinbefore described.EXAMPLES

[0157] METHODS

[0158] Antibodies and reagents

[0159] Antibodies for western blotting. NFKB2 (1:1000; 3017, CST), p-EZH2 (1:1000; PA5114574, Thermo), EZH2 (1:1000; 491043, Thermo), EED (1:1000; PA534430, Thermo), SUZ12 (1:1000; 3737S, CST), p-IREla (1:1000; ab243665, Abeam), IREla (1:500, sc-390960, Santacruz), sXBPl (1:500; sc-133132, Santacruz), p-eIF2a (1:1000; 9721, CST), eIF2a (1:500; sc-133132, Santacruz), ATF6a (1:500; sc-166659, Santacruz), GAPDH (1:10000; sc-32233, Santacruz), HA antibody (1:1000, sc-7392, Santacruz), pCDKl / 2 (1:1000; 4539S, CST), CDK1 / 2 (1:500; sc-53219, Santacruz), H3K27me3 (1:1000; 9733S, CST), H3 (1:1000; sc-517576, Santacruz), FOXO3 (1:500; sc-48348, Santacruz), ZFP36 (1:500; sc-374305, Santacruz), anti-rabbit IgG-HRP conjugated secondary antibody (1:10000; sc-2357, Santacruz) and anti-mouse IgG-HRP conjugated secondary antibody (1:10000; sc-516102, Santacruz).

[0160] Antibodies for ChlP. H3K27me3 (9733S, CST); 4 pg / 8 x 106cells, EZH2 (491043, Life technologies); 8 pg / 8 * 106cells, HA Ab (901503; Genomax); 4 pg / 8 x IO6cells, Anti-rabbit IgG (7074S; CST); 4 pg / 8 10ficells.

[0161] The inhibitors used. Bortezomib for cell culture use (5.04314.0001CN; Merck Sigma), Bortezomib for in vivo use (HY-10227; MedChem Express), Lenalidomide for cell culture and in vivo use (HY-A0003; MedChem Express), Ro-3306-CDK1 / 2 inhibitor (HY-12529; MedChem Express), MG132 (abl41003; Abeam), Cyclohexamide (C1988; Sigma).

[0162] Cell culture

[0163] Human MMCLs, including KMS11, U266, RPMI8226, JJN3, XG7 and H929,were gifts from Prof. Leif Bergsagel (Mayo Clinic, Scottsdale, AZ, USA). The MM1. S cell line was obtained from ATCC, while LP1 and MOLP8 were obtained from the German Collection of Microorganisms and Cell Cultures. BTZ-resistant (BTZ-R RPMT8226), lenalidomide resistant (Len-R KMS11) and their parent sensitive cells were obtained from Dr. W. J. Chng (Cancer Science Institute of Singapore, Singapore). Isogenic lenalidomide-resistant (LenR KMS11) cell line was established in the presence of escalating doses of lenalidomide over an extended period. Whole-exome sequencing was performed to examine for geneticalterations in LenR cells85. All the cells were authenticated by short tandem repeat profiling. Cell lines were tested to be mycoplasma-free using Mycoplasma PCR Detection Kit (G238; Abm) prior to experiments. MM cell lines were cultured in RPMI 1640 media with 2.05mM L-Glutamine (SH30027.01; Hyclone). XG7 was supplemented with 2 nM IL-6 (200-06-20UG; PeproTech) while H929 was supplemented with 0.05mMP-mercaptoethanol (444203; Sigma). HEK 293 T cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 4mMglucose (high glucose) (SH30243.01; Hyclone) and passaged with 0.25% Trypsin / EDTA (25200072; Gibco). All cells were supplemented with 10% Fetal Bovine Serum (F7524, Sigma) and cultured in a humidified 5% CO2incubator at 37 °C.

[0164] Western blotting

[0165] Cell lysates were prepared using ice-cold RIPA lysis buffer (lOmM TrisHCl, pH 8.0, ImM EDTA, 0.5mM EGTA, 1% Triton x-100, 0.1% Sodium Deoxycholate, 0.1% SDS, 140mM NaCl, 0.5mM DTT, 0.3mM NaVO3) with 1 x protease inhibitor cocktail (5056489001; Merck). 30-50 pg of total protein was resolved on 8-14% acrylamide gel (as per experimental requirement) under reducing conditions and transferred to 0.2 pm polyvinylidene difluoride membrane in Tris-glycine buffer. Membrane was blocked for 1 h in 5% non-fat milk, in Trisbuffered saline-tween 20 (TBST) buffer / 5% BSA in TBST. Blocked membrane was washed 3 times with TBST buffer. Probing with primary antibody (ab) was conducted for 2 h at room temperature (RT) / overnight at 4 °C, followed by 3× washing with TBST for 10min each. Incubation with HRP conjugated secondary Ab was performed for 1 h at RT, followed by 3× washing with TBST for 10 min each, and further developed using Clarity Western ECL substrate (1705062, BioRad). Images were taken with Chemidoc XRS imaging system (BioRad) and quantified using GelQuant. NET software provided by biochemlabsolutions. com (CA, USA).

[0166] Gene expression analysis

[0167] For gene expression analysis, cells were harvested for RNA using TRIzol reagent (15596026; Invitrogen) following manufacturer’s instructions. 500 ng-1 pg of RNA was used to prepare cDNA using TOYOBO ReverTra Ace qPCR RT master mix kit (FSQ-301; TOYOBO) as per manufacturer’s protocol. Quantitative polymerase chain reaction (qPCR) was performed using SYBR green chemistry (Biorad system) using primers as mentioned in Table 2. GAPDH was taken as internal control.Lentiviral production and transduction

[0168] Two million 293T cells (maintained in DMEM supplemented with 10% FBS) were seeded in a poly -L-ly sine-coated 100mm dish 1 day prior to transfection so that it reaches a confluency of -70% at the day of transfection. Cells were then transiently transfected using the four-plasmid system: 2.5 pg pRSV-Rev, 6.5 pg pMDLg / pRRE, 3.6 pg pCMVVSVG and 10 pg of plasmid of interest (CRISPR constructs / PLKO.l-shRNA constructs / LeGO-lnc PLUM overexpression constructs) and topped up to final volume of 500 pl with distilled H2O The plasmid mix was then added drop wise to 500 pl of 2x HBS buffer; pH 7.07 (280mM NaCl, 50mM HEPES, 1.5mM Na2HPO4, lOmM KC1, 12mM Dextrose) and incubated for 20min at RT followed by adding to the cells dropwise. After 6-8 h of incubation, medium was discarded, and cells were washed 3 times with PBS followed by replenishment with 8ml of fresh medium (70% RPMI and 30% DMEM). The supernatant containing lentiviral particles was collected at 24 h post-transfection and passed through a 0.45 pm syringe filter before being stored at -80 °C. For transduction, spin infection method was adopted from. In brief, 5 × 105of target cells suspended in 500 μl of complete medium were mixed with 2× volume of lentivirus. Polybrene was added to a final concentration of 8 pg / ml. The cells were then centrifuged at 400 x g for 45min at RT and gently resuspended in the same tube to be seeded in a 6-well plate. After 24 h, virus was removed, and cells were resuspended in fresh medium. After another 24 h, cells were selected using specific drug pressure for 24-72 h followed by recovery of 3-7 days (as per different plasmid system used)

[0169] CRISPR-Cas9 deletion of super-enhancer (SE) region

[0170] For PLUM SE deletion, gRNAs were designed using the Broad Institute GPP sgRNA Designer / CRISPick87 to target the SE region proximal to PLUM. Forward guide (gl) sequence was cloned into TLCV2 lentiviral vector (Addgene plasmid #99376, a gift from Kristen Brennand) and reverse guide (g2) sequence was cloned into pHIV-dTomato lentiviral vector (Addgene plasmid # 21374) as previously described. The following oligos were used to generate the TLCV2-PLUM-g1 and dTOM-PLUM-g3 plasmid to make a CRISPR deletion of -3 kb within the SE region.

[0171]

[0172]

[0173] Lentiviral production and transduction of target cells was performed using protocol mentioned in above method. Cells were first transduced with lentiGuide-Hygro-dTomato g3 construct and selected with 300 ng / ml hygromycin for 10 days. The cells containing lentiGuide-Hygro-dTomato plasmids were then transduced with the TLCV2-gl plasmid and selected with 0.5 pg / ml puromycin for 24 h followed by recovery of 3 days.

[0174] To assess super enhancer deletion efficiency of the pool of sorted cells, genomic DNA was extracted, and genotyping was performed using primers flanking the genomic target region. A shorter PCR product is expected for deleted alleles compared to the uncut control (Figure 8c). The PCR product for the shorter band was sequenced using Sanger sequencing to confirm the deletion of the region (Figure 8b). Primers used are listed in Table 1.

[0175] Short hairpin RNA-expressing plasmid construction

[0176] All the shRNA sequences (Table 1) were designed manually according to the TRC design rule and cloned into PLKO.1 plasmid (Addgene plasmid #8453) Scramble RNA sequence was used as control. Cloning was confirmed by double digestion and sequencing. Transduction was performed using lentiviral system. Knock down efficiency for / 77 / / V / was measured using qPCR (primer sequence in Table 2) and for other proteins by immunoblotting.

[0177] Rapid amplification of cDNA ends (RACE) assay

[0178] Total RNA was isolated from MMCLs (KMS11, LP1 and JJN3) using TRIzol reagent (15596026; Invitrogen) according to the manufacturer’s protocol. 5’ and 3’ RACE was performed according using SMARTer kit as per manufacturer’s protocol (SMART er). In brief, pair of / 77 / Af-specific primers targeting specific exons of the isoforms (predicted on the Ensembl database) were designed. 573’ RACE PCR products were then ligated into the pRACE vector, and multiple clones were sequenced with M13F primer and aligned using the Unipro Ugene Alignment Editor to identify the major isoforms of PLUM expressed in MMCLsRNA fluorescence in-situ hybridisation (RNA-FISH)

[0179] Custom Stellaris™ RNA FISH Probes were designed against PLUM with Fluor® Red 635 Dye by utilising the Stellaris RNA FISH Probe Designer (LGC, Biosearch Technologies, Petaluma, CA). The myeloma cells were hybridised with the PLUM Stellaris RNA FISH probe set labelled with Fluor® Red 635 Dye (Biosearch Technologies), following the manufacturer’s instructions with some modifications. In brief, 3 x 106cells were collected in tube, fixed with 3.7% formaldehyde for 10-15 min and permeabilised in 0.5% Triton x-100 in PBS for 15 min Cells were then washed with PBS and incubated for 5min in Stellaris RNA FISH buffer A on ice. Hybridization of FISH probes was carried out overnight at 50 °C in 100 L of Stellaris FISH hybridization buffer containing probe (500nM) in a dark humidified chamber. In the next day, after washing and incubation for 30min with FISH buffer A, cells were counterstained with DAPI (5 ng / ml in wash buffer A) for lOmin in dark. After another wash with FISH buffer B, cells were resuspended in a small drop of vectashield mounting medium to prepare the glass slide for imaging. All the steps were performed in 1,5ml tube and centrifugation was performed at 200 x g for 2 min. Imaging was performed using Carl Zeiss confocal microscope with an objective magnification of 63 x.

[0180] Immunofluorescence (IF)

[0181] Post RNA-FISH hybridization step, cells were washed and incubated in wash buffer A and wash buffer as mentioned in the above methods. After that, cells were blocked with 5% BSA in PBST for 20 min in dark. After blocking, washing was performed 2 times with PBS and cells were incubated with 500 pL of primary antibody (EZH2 Ab used: 1:500 in 5% BSA) for 1 h in dark. Primary Ab was then removed, and cells were washed 2 times with PBST. Secondary antibody (GFP conjugated: 1:500 in 5% BSA) incubation was performed for 1 h in dark followed by washing 3 times with PBST. In the third wash, DAPI (5 ng / ml) was added and incubated for lOmin in dark. Thereafter, mounting, slide preparation and imaging were performed as per above method

[0182] Site-directed mutagenesis (SDM)

[0183] Mutagenesis was performed using Q5 site directed mutagenesis kit (E0554; NEB) following manufacturer’s protocol. In brief, mutagenic primers were designed using NEBase Changer tool, with required mutation in the forward primer for all the constructs. Exponential amplification was performed using Q5 hot start high fidelity 2x master mix and 1 pl of PCR product was then taken for Kinase, Ligase, and Dpnl (KLD) treatment, using KLD enzymemix for 5min, at RT. Following treatment, 5 pl of the KLD mix was transformed in NEB 5-alpha competent Escherichia coli cells (C2987S, NEB). Positive colonies were selected for plasmid isolation, and mutants were confirmed by sequencing, using vector specific forward and reverse primers.

[0184] Probe preparation and RNA-protein pull down assay

[0185] To generate template for in vitro transcription, two primers were designed for each target transcript carrying a T7-tag in the forward primer (5’ -CGTTAATACGACTCACTATAGG target sequence-3’) (5’-CGTTAATACGACTCACTATAGG-3’ - SEQ ID NO: 26) and an aptamer sequence in the reverse primer (5’-CATGGCCCGGCCCGCGACTATCTTACGCACTTGCATGATTCTGGTCGGTCCCAT GGATCC target sequence (reverse complement)-3’) (5 -CATGGCCCGGCCCGCGACTATCTTACGCACTTGCATGATTCTGGTCGGTCCCAT GGATCC-3’ - SEQ ID NO: 27). The transcripts were amplified using Q5 polymerase (M0491L; NEB) with touch-up PCR program. Amplified PCR product was purified using ethanol purification method followed by in vitro transcription as follows: 6 µl 10× transcription buffer, 8 µl 25 nMNTPmix (R0481; Life technologies) and 1 pl of T7 RNA polymerase (200 U / pl)(EP0113, Life technologies) were mixed with 1 pg of PCR product topped up the total volume of 60 pl. Incubation was performed at 37 °C for 4-6 h followed by purification using ethanol purification method and the RNA templates were proceeded for pull down. 25 pg of biotinylated RNA was bound to 50 pl of MyOne Cl beads (65001; Invitrogen) in RNA binding buffer (100mM NaCI, lOmM MgC12, 50mM HEPES, ph7.4, 0.5% Igegal CA-530) for 30 min at 4 °C on a rotator. Beads were washed 3 times with RNA wash buffer (250mMNaCl, 10mMMgC12, 50mMHEPES, ph7.4, 0.5% Igegal CA-530) before incubation with 500 pg of nuclear protein extract, cOmplete protease inhibitor, 40units of RNase inhibitor (AM2696; Life technologies) and 20 pg yeast tRNA (M0491L, Life technologies) for 1 h at 4 °C on a rotator. After washing with wash buffer 3 times, bound proteins were eluted with 25 pl 2* laemmli buffer by heating at 95 °C for 5min.

[0186] RNA pull-down samples were separated on a 4-12% NuPAGE Bis-Tris precast gel (Thermo Fisher Scientific) for lOmin at 170 V in L MOPS buffer. The gel was fixed using the Colloidal Blue Staining Kit (Thermo Fisher Scientific) and processed as a single fraction. For in-gel digestion, samples were destained in destaining buffer (25mM ammonium bicarbonate; 50% ethanol), reduced in lOmM DTT for 1 h at 56 °C followed by alkylationwith 55mMiodoacetamide (Sigma) for 45min in the dark. Tryptic digest was performed in 50mM ammonium bicarbonate buffer with 2pg trypsin (Promega) at 37 °C overnight. Peptides were desalted on StageTips and analysed by nanoflow liquid chromatography on an EASY-nLC 1200 system coupled to a Q Exactive HF mass spectrometer (Thermo Fisher Scientific). Peptides were separated on a CIS-reversed phase column (25 cm long, 75 pm inner diameter) packed in-house with ReproSil-Pur C18-AQ 1.9 pm resin (Dr Maisch) The column was mounted on an Easy Flex Nano Source and temperature controlled by a column oven (Sonation) at 40 °C. A 105- min gradient from2 to 40% acetonitrile in 0.5% formic acid at a flow of 225 nl / min was used. Spray voltage was set to 2.2 kV. The QExactive HF was operated with a TOP20MS / MS spectra acquisition method per MS full scan. MS scans were conducted with 60,000 at a maximum injection time of 20ms and MS / MS scans with 15,000 resolutions at a maximum injection time of 50 ms. The raw files were processed with MaxQuant version 1.5.2.890 with preset standard settings for label-free quantitation using the MaxLFQ algorithm91. Carbamidomethylation was set as fixed modification, while methionine oxidation and protein N-acetylation were considered as variable modifications Search results were filtered with a false discovery rate of 0.01. Known contaminants, proteins groups only identified by site, and reverse hits of the MaxQuant results were removed and only proteins with LFQ intensities in four replicates of at least one condition of each pair-wise comparison were kept. Missing LFQ intensities were randomly imputed from a normal distribution around the lowest 5% of LFQ intensities based on the means of three iterations. Proteins that were enriched with a fold change >4 and p-value < 0.01 on the full-length PLUM compared to either AExonl or AExon7 constructs was considered as candidate RBP(s).

[0187] RNA immunoprecipitation (RIP) — qPCR

[0188] Cells were cross linked with 37%formaldehyde (to a final concentration of 1%) in medium and incubated for 15 min at RT. Cross-linking was neutralized by adding 2Mglycine (to a final concentration of0.2M) for 5 min atRT. Crosslinked cells were washed twice with TBS and proceeded for nuclear fraction isolation using nuclear isolation buffer (1 28M sucrose; 40mM Tris-HCl, pH 7.5; 20mM MgC12; 4% Tritonx-100) with frequent mixing for 20min. Nuclei pellet was collected by centrifugation at 2,500 x g for 15min, which was resuspended in freshly prepared RIP buffer (150mM KC1; 25mM Tris, pH 7.4; 5mM EDTA; 0.5mM DTT; 0.5% NP-40; 100 U / mL RNase inhibitor SUPERase In™ (added fresh each time);Protease inhibitors (added fresh each time). Resuspended nuclei were split into two fractions: control and target, followed by shearing 3-5 rounds of low power sonication using Bioruptor (Diagenode) for 3 cycles (30 s ON and 30 s OFF). The lysate was subsequently cleared by centrifugation at 14,000 rpm for lOmin and proceeded for RIP. 10 pg of Ab was added to 1 mg of supernatant and incubated for 6 h at 4 °C in a rotator. Subsequently, protein A / G beads (40 pl) was added and incubated for another 1 h at 4 °C. Beads were pelleted down at 2500 rpm for 30s and washed 3 times with RIP buffer. After second wash, 10% of the beads was kept for SDS-PAGE analysis to confirm the IP and remaining beads were used to isolate the co-precipitated RNA using TRIzol reagent following manufacturer’s protocol. DNase treated and purified RNA was then reverse transcribed, and qPCR was performed using target RNA specific primer pairs.

[0189] Co-immunoprecipitation (Co-IP)

[0190] For Co-IP, nuclear fraction was extracted and 500 pg of nuclear extract was then incubated with 5 pg of primary Ab of interest or its corresponding IgG control diluted in IP lysis buffer at Img / ml concentration in a 1.5ml tube. Incubation was performed overnight at 4 °C in a rotator, followed by addition of 50 pl of homogenized Protein-G Dynabeads (10004D; Life Technologies) per each sample. The mixture was incubated in a rotator for 30 min at RT. Washing was done twice with wash buffer I (50mM Tris, pH 7.5; 500mM NaCl; ImM EDTA; 0.5% NP-40; 0.5% Triton x-100, 0.05% Tween 20) and twice with wash buffer II (50mM Tris, pH 7.5; 150 mM NaCl; ImM EDTA; 0.5% NP-40; 0.5% Triton x-100, 0.05% Tween 20), 5min each at 4 °C. After the last wash, beads were transferred to a fresh tube and immunoprecipitated protein was eluted using 35 pl of 2x laemmli buffer by heating at 99 °C for lOmin.

[0191] Annexin V / PI apoptosis assay

[0192] Cells were harvested and washed twice with cold PBS. Pellet was resuspended in 1 x binding buffer containing Annexin V-Alexa Fluor™ 350 (A23202; Invitrogen) and Propidium Iodide (PI, P4864; Merck) following the manufacturer’s instructions The samples were analysed by flow cytometry (BD LSRFortessa™ x-20) to gate for apoptotic and live cells. Statistical analysis was done using the FlowJo vl0.2 software.MTT assay for IC50 survival curve

[0193] Cell growth inhibition and cell viability was determined by MTT assay. In brief, 50,000 cells were seeded / well in a 96-well plate one day prior to treatment with serial dilution of drug concentration (dug volume 10 pl / well). Following drug treatment, 10 pl of 0.5mg / ml MTT reagent was added to each well after 24 h of treatment with BTZ and 4 days of treatment with lenalidomide and incubated for 2 h in CO2 incubator. Then, 150 pl of DMSO was added into each well, mixed well and incubated further in a 37 °C incubator until all the waterinsoluble formazan crystals were fully dissolved. Optical density (OD) was measured with a plate reader at a wavelength of 570 nm with a reference filter of 650 nm. The cytotoxicity was expressed as relative viability with the percentage of cell survival in the negative control (without drug treatment) taken as 100%. Relative viability = [(experimental absorbance -background absorbance) / (absorbance of untreated control - background absorbance)]x100%. The half maximal inhibitory concentration (IC50) values of each drug were calculated using the survival curves, which plotted fractional cell viability against logarithm of drug dose, and IC50 values were calculated by Prisms software (GraphPad Software).

[0194] RNA and EZH2 structure prediction for in-silico docking

[0195] For modelling the full-length PLUM and exon 7 of PLUM, several tools were evaluated: 3dRNA, RosettaFOLD2NA, RNAcomposer, DeepFoldRNA, trRosettaRNA and DRfold. Based on RNA scoring functions (rsRNASP and cgRNASP), the PLUM-FL structure modelled by 3dRNA and exon 7 structure modelled by RNAComposer were selected for docking studies PRC2 / EZH2 complex structures were retrieved from the RCSB Protein Data Bank (PDB-5HYN). Due to lack of the complete structure of EZH2 from PDB id 5HYN (165 of the 746 residues were absent), both homology modelling and ab initio methods have been used to predict the complete structure. SWISS-PROT was used for homology modelling, while ab initio tools included AlphaFold 2, RosettaFold2, Phyre2 and I-TASSER. Among these, the remodelled structure of EZH2 obtained using I-TASSER was chosen for docking studies based on its model quality and completeness. For in-silico docking, HDockl 03 was used to dock PLUM-exonl and PLUM-FL RNA with the modelled EZH2 protein structure. The docking scores were evaluated using HDock’s knowledgebased iterative scoring functions ITScorePP and ITScorePR. The top 3 docked structures for each RNA (PLUM-FL and PLUM-exonT) were selected for further analysis and in vitro validation experiments.RNA-electrophoretic mobility shift assay (RNA-EMSA)

[0196] RNA-EMSA was performed using LightShift® Chemiluminescent RNA EMSA Kit (Thermo Scientific; 20158) as per manufacturer’s instructions. Briefly, 4 pg of purified proteins of interest were incubated with 1 nM of biotinylated RNAs (synthesized using services of GenScript, Singapore) for 30min at RT, then loaded on 8% native polyacrylamide gel in 0.5 x TBE. RNA was then transferred to nitrocellulose membrane, followed by UV cross-linking at 120 mJ / cm2 for Imin. After proper blocking and washing of the cross-linked membranes, biotin-labelled RNA-protein complex was detected by chemiluminescence using Streptavidin-Horseradish Peroxidase Conjugate. Labelled random RNA sequence was used as negative control (NC) for binding specificity and unlabelled RNA was used as competitive binder to confirm the binding specificity.

[0197] RNA-seq library construction, data processing and analysis

[0198] The TRIzol -isolated total RNA samples were quantitated by Qubit RNA BR Assay (Q10210; Thermo Scientific) and assessed for their quality by Agilent bioanalyzer run using RNA 6000Nano Kit to determine the RIN scores for the samples. The RNA samples were then treated with the RNase-free, Turbo DNase 1 (AM2238; Thermo Scientific), followed by poly (A) mRNA enrichment using NEBNext® Poly(A) mRNA Magnetic Isolation Module (E7490S; NEB) according to manufacturer’s instructions. Subsequently, the RNA library was prepared using the NEBNext® Ultra™ II Directional RNA Library Prep Kit (E7760S; NEB) according to manufacturer’s recommendation. All libraries underwent 8 cycles of PCR with the recommended conditions. NEBNext oligos from NEB were ligated to allow for multiplexing of samples. After library preparation, the samples were quantitated and run on the Bioanalyzer using DNA High Sensitivity DNA Analysis kit to determine library molarities. Libraries were pooled, which was then diluted to a final concentration of 5 nM. Pooled and diluted library was sent for next generation RNA-seq by NovogeneAIT Genomics Singapore Pte Ltd. Library was loaded on a HiSeqX and sequencing was performed at an output of 110G per lane. Each sample was prepared in biological triplicates to ensure the reliability of RNA-seq data. Reads were mapped to GRCh38 using STAR (2.7.4a) and counted using featureCounts (v2.0.1) against the GENCODE v42 annotation prior to differential testing with DESeq2 (vl.34.0).Chromatin immunoprecipitation-Quantitative PCR (ChIP-qPCR) and ChIP-seq library preparation

[0199] ChIP-qPCR and ChIP-seq were performed using methods known in the art. In brief, a total of 15 x 106were crosslinked with 1% formaldehyde for 12 min at RT. Crosslinking was stopped by incubating the reaction with 0.125M glycine. Cells were spinned down and washed once with cold DPBS. Washed cell pellet was resuspended in 2 ml SDS buffer (lOOmM NaCl, 50mM Tris. Cl, pH8, 5mM EDTA, 0.5% SDS, lx protease inhibitor) and incubated for lOmin on ice Subsequently, cells were centrifuged (1200 rpm, 6 min, 4 °C), and the nuclear pellet was resuspended in 1.5ml ChIP buffer (2 parts of SDS lysis buffer, 1 part of Triton buffer [lOOmM NaCl, lOrnM Tris. Cl, pH8, 5mM EDTA, 5% Triton-xlOO] and lx protease inhibitor) and subjected to 20 cycles of high power (30 s ON and 30 s OFF) sonication to obtain a fragment size of 200-500 bp, which was confirmed by running on 2% agarose gel. The mixture was centrifuged (12,000 × g, 1min, 4°C), and the supernatant was collected. Sheared chromatin was then precleared with 40 pl of BSA-blocked Protein G agarose beads (50% slurry) with continuous rocking at 4 °C for 2 h. For immunoprecipitation (IP), appropriate amount of primary antibody (8-10 pg) was added to the precleared chromatin topped up to 1 ml reaction with IP buffer. IP reaction was incubated at 4 °C overnight in a rotator. Following incubation, 60 pl of blocked protein G agarose beads were added to each IP reaction and incubated at 4 °C for 6 h. Beads were captured and washed 4 times (5min each) in sequence with Mixed Micelle buffer (150mM NaCl, 20mM Tris. Cl, pH8, 5mM EDTA, 5.2% w / v sucrose, 1% Triton-xlOO, 0.2% SDS), Buffer 500 (0.1% sodium deoxycholine, ImM EDTA, 50mMHEPES, pH7.5, 500mMNaCl, l%Triton-X100), LiCl buffer (0.5% sodium deoxycholine, ImM EDTA, 250mM LiCl, 0.5% NP-40, lOmMTris. Cl, pH8) and TE buffer (lOmMTris. Cl, pH7.4, ImMEDTA). Immunoprecipitated complexes were eluted by adding 200 pl elution / decrosslink buffer (10% SDS and 0.084 g NaHCO3 to a final volume of 10 ml with H2O) to the beads containing 20 pg RNaseA and lOpl of 5M NaCl. The reaction was incubated at 65 °C with agitation for 1 h followed by overnight incubation without agitation. DNA was extracted using QIAquick PCR purification kit (Qiagen) Locus-specific chromatin immunoprecipitation-quantitative PCR (ChIP-qPCR) was performed with SsoAdvanced Universal SYBR Green Supermix (1725272; BioRad) using primers listed in Table 3. For ChIP-seq library preparation, immunoprecipitated DNA was quantified using Qubit™ 1× dsDNA High Sensitivity (HS) and Broad Range (BR) Assay Kits (Q33231; Life Technologies). Subsequently, library was prepared using NEBNext® Ultra™ II DNA LibraryPrep Kit for Illumina® (E7645S; NEB and E7103S; NEB) according to manufacturer’s recommendations. After library preparation, the samples were quantitated and run on the Bioanalyzer using DNA High Sensitivity DNA Analysis kit (5067-4626; Agilent) to determine library molarities. Libraries were pooled, which was then diluted to a final concentration of 5 nM. Pooled and diluted libraries were sent for next-generation RNA-seq by NovogeneAIT Genomics Singapore Pte Ltd Library was loaded on a HiSeqX and sequencing was performed at an output of 110G per lane. Each sample was prepared in biological triplicates to ensure the reliability of ChlP-seq data.

[0200] ChlP-seq data processing and analysis

[0201] All ChIP-seq data was processed through the ENCODE ChIP-seq pipeline (GRCh38; in tf or histone mode). ChIPseqSpikeInFree normalization was applied to the PLUM KD H3K27me3 experiment to enable detection of global changes in histone modificationsl06. After normalization, ChlP-seq coverage profiles and genome tracks were generated using deeptools and pygenometracks respectively. For differential analyses, counts around each TSS (2 kb upstream and 500 bp downstream) were obtained using featureCounts v2.0.1 and normalized using ChIPseqSpikeInFree (v1.2.4) scaling factors prior to DESeq2 (vl.34.0) differential testingl09,110. H3K27me3 levels associated with each TSS were matched with differential gene expression on the basis of shared gene identifiers and visualized in R (ggplot2).

[0202] CoMMpass and CCLE dataset analysis

[0203] Indexing, subtyping and differential testing of CoMMpass dataset IA14a were performed using methods known in the art. Pre-normalised CCLE expression data (SRP186687) was retrieved from LncExpDB and annotated using LncBook 2.0 prior to visualization in R (ggplot2).

[0204] GO analysis

[0205] GO annotation was conducted using clusterProfiler GO term summarization was performed by semantic clustering (Jiang) using GOSemSim in combination with hierarchical clustering (hclust). GSEA was conducted against the ranked gene list (FDR < = 0.1) using the GSEA function and the HALLMARK gene sets retrieved from MSIGdbl 14.Steric antisense oligonucleotide (ASO) designing and treatment

[0206] Designing of steric ASOs (mixmers) was done using both 2nd and 3rdgeneration mixed backbone ASO modifications as they do not activate RNase H activity but produce their biological effects by using steric hindrance for binding of bulky protein complexes. ASOs were either 2’-O-Methoxyethyl (2’MOE) / locked nucleic acid at adenosine residue (LNAa) or 2’MOE / locked nucleic acid residue at cytosine residue (LNAc) modified. The designed ASOs were synthesized using services of GenScript, Singapore. For in vitro treatment, Lipofectamine™ RNAi- MAX Transfection Reagent (13778075; Tnvitrogen) was used For in vivo treatment, ASO was administered via intra-tumoral (i.t.) injection.

[0207] Mouse xenograft experiment

[0208] 6-10 weeks old Balb / c RAG - / - IL2Rγ - / - mice (both male and female) were used to perform in-vivo mouse xenograft experiment to assess the role of PLUM and s-ASO on tumour growth and BTZ drug response as per detailed protocol mentioned in ref. 105. Briefly, for BTZ drug response studies: 5 × 106of vector control and PLUM overexpressed (OE) cells were resuspended in DPBS containing 50% Matrigel (BD) and injected subcutaneously into the flank of the mice (10 mice / group). Upon reaching the tumour size of ~150mm3, mice from each group of 10 were randomly divided into two sub-groups of 5 mice each to be treated by vehicle (DMSO) and BTZ (Img / kg of body weight): Subgroup 1-VC withDMSO (N = 5); Sub-group 2 -VC with BTZ (N =5); Subgroup 3 -PLUM OE with DMSO (N =5); Sub-group 4-PLUM OE with BTZ (N = 5). BTZ was administered intraperitoneally up to 5 doses every 3-4 days twice weekly and tumor sizes were measured using an electronic digital caliper. Tumor volume (mm3) was calculated as 1 / 2 × L × W2. For survival evaluation, mice were euthanized when the tumor size reached 2000mm3(humane end point).

[0209] ASO and BTZ combination drug response studies

[0210] 5×106of PLUM overexpressed (OE) cells were resuspended in DPBS containing 50% Matrigel (BD) and injected subcutaneously into the flank of the mice (24 mice). Upon reaching the tumour size of ~150mm3, mice were randomly divided into four treatment groups: Treatment group 1 - DMSO with NC-ASO (N = 6); Treatment group 2 - BTZ (Img / kg) (N=6); Treatment group 3 - s-ASO-gl2 (15 pg) (N = 6); Treatment-group 4 - BTZ with s-ASO-gl2 (N = 6). BTZ was administered intraperitoneally (I. P.) and s-ASO was administered intra-tumorally (i.t.) up to 5 doses every 3 to 4 days twice weekly. Tumor sizes were measured using an electronic digital caliper and tumor volume (mm3) was calculatedas 1 / 2 * L - W2For survival evaluation, mice were euthanized when the tumor reached 2000mm3(humane end point). BTZ was injected intra-peritoneally (I. P.) at a concentration of lOmg / kg of body weight diluted in PBS (total volume of 200 pl) and sASO was injected intra-tumorally (i t) at a total concentration of 15 pg diluted in PBS (total volume of 100 pl).

[0211] Statistics and reproducibility

[0212] All experiments which are statistically validated are representative of at least 2-3 independent experiments. All MTT experiments were done in triplicate wells and normalized as indicated in figure legends. Experimental replicate numbers are designated as “N” in the figure legends of each figure. Data are presented as mean ± SEM. Unpaired student t-tests / two-way ANOVAs were performed to calculate the p-values unless otherwise indicated using Graph Pad Prism 5.0 (GraphPad software, La Jolla, CA, USA). For in vivo studies, tumor measurement, treatment and analysis were performed in a blinded manner. Tumour volume significance was determined by two-sided multiple t-test and survival analysis was computed by the Kaplan-Meier method with statistical significance being determined by two-sided log-rank (Mantel-Cox) test. Animals were randomized, with each group receiving mice with similar tumor size or similar body weight. As for in vitro studies, randomization and blinding of cell lines was not possible; all cell lines were treated identically without prior designation. All statistical tests were performed with the assumption of similar variance for all test groups No inclusion / exclusion criteria were predecided in any of the experiments. Fold change, p-values and adjusted p-values (IHW) were calculated in analysis, p-values < 0.05 are considered statistically significant.

[0213] Steric antisense oligonucleotide

[0214]

[0215] ,

[0216] wherein:

[0217] m = 2 ’-O-M ethoxy ethyl (2’MOE) modification;

[0218] * = phosphorothioate (PS) linkage; and

[0219] underline = locked nucleic acid.RESULTS

[0220] PLUM is p52-regulated and upregulated in NF-KB+ high-risk myeloma subtypes To understand the role of ncNF-KB regulated IncRNAs in MM progression, RNA seq analysis of control versus NF -KB / p52 KD MM cells was performed, which identified several p52-regulated non-coding transcripts showing negative correlation with the expression of p52 (Fig. la). The differentially regulated transcripts were integrated with the transcriptomic profiles of patient samples from MMRF CoMMpass study (NCT01454297) and identified an uncharacterized IncRNA - LTNC02362 (termed as PLUM) associated with NF-KB mutant, high-risk MM subtypes (Fig. la). The direct regulation of PLUM expression by NF-icB / p52 was further confirmed by CRISPR-mediated KD of NF-KB / p52 in two NF-KB mutant multiple myeloma cell lines (MMCLs), KMS11 and LP1, which resulted in the downregulation of PLUM expression (Fig. 8a, b). Additionally, MMCLs carrying activating mutations in NF-KB pathway (NF- B+) display elevated PLUM expression compared to non-mutant (NF-KB-) MMCLS (Fig. 8c), correlating with NF-KB activity.

[0221] To determine the clinical relevance of PLUMm' MM, the expression levels of PLUM were examined in various MM patient subtypes and cancer cell lines. Using MMRF CoMMpass dataset, PLUM was found to be overexpressed in patient samples harbouring high-risk, aggressive MM subtypes displaying hyperactivation of NF-KB pathway (subtyping data published in ref. 14) (Fig. lb). Amongst the p52-regulated non-coding transcripts, PLUM s one of the top upregulated IncRNAs in the MAF t(14, 16) and HRD low TP53 high-risk subtypes carrying NF-KB activation (NF-KB+) (Fig. lb, c). Additionally, the transcriptomic data from MM patients undergoing VRd regimen therapy was analysed using CoMMpass metadata (Best response). Patients showing Complete Response (CR), Stringent Complete Response (SCR) or Very Good Partial Response (VGPR) were grouped as responsive and patients with Stable Disease (SD) or Progressive Disease (PD) were grouped as non-responsive. Interestingly, PLUM expression was found among the significantly upregulated genes in non-responsive (SD or PD) versus responsive (CR, SCR or VGPR) patients under differential testing (DESeq2, FDR < 0.1), with non-responsive patients showing approximately twofold increase in expression (Fig. Id). PLUM is also selectively upregulated in MMCLs compared to other 51 cancer types and other p52-regulated IncRNAs like NR2F2-AS1 and MALT1-AS1 found in our earlier analysis, suggesting its aberrant expression could be linked to MM disease (Fig. le). These findings demonstrate theplausible association of PLUM overexpression with NF-KB activated, high-risk subtypes of MM and poorer treatment response.

[0222] Next, the expression and cellular localisation of PLUM in MM cells was characterised. 5’-3’RACE assays revealed 3main isoforms of PL UM in NF-KB +MMCLs (KMS11 and LP1), whereby isoform 201 (Batch 3) represents approximately 40% of all isoforms (Fig. If and Fig. 8d, e). Overexpression studies of PLUM using a HA-tagged construct verified this IncRNA does not code for any protein or small peptides (Fig 8f). RNA-FISH and sub-cellular fractionation studies further indicated PLUM is predominantly localised in the nucleus (Fig. 1g and Fig. 8g-i).

[0223] PLUM confers enhanced proliferation and VRd resistance in MM

[0224] To understand the functional relevance of PLUM in MM, both gain of function and loss of function approaches were used. Overexpression of PLUM (FL-PLUM isoform 201) in both NF-KB +MMCLs (KMS11, LP1, MM.l. S) and NF-KB- MMCLS (XG7 and H929) resulted in their enhanced proliferation (Fig. 2a and Fig. 9a-d), whereas shRNA KD of / 7.7 / A7 induced the apoptosis of NF-KB+MMCLS post 6 days lentiviral transduction (Fig. 2b and Fig. 9e, f). Consistent with the oncogenic functions a? PLUM treatment with ASOs designed to degrade PLUM reversed the proliferative phenotype of NF-KB +MMCLS (KMS11 and LP1) but not that of NF-KB-MMCLS (XG- 7 and H929) (Fig. 9g-i). There was no induction of apoptosis as well in NF-KB-MMCLS (XG-7 and H929) on treatment with PLUM targeting degradative ASOs (Fig 9j). These data confirmed the identification of aNF-KB / p52-regulated oncogenic IncRNA, PLUM, associated with myeloma progression.

[0225] Furthermore, consistent with the elevated expression of PLUM in VRd non-responsive patients, MMCLs carrying resistance to VRd components also displayed elevated PLUM expression compared to their parental sensitive lines (Fig. 10a). Hence, its chemoresistance functions in both NF-KB+ and NF-KB-MMCLS were validated against two of the main drugs, bortezomib (BTZ) and lenalidomide (Len). Overexpression of PLUM in NF-KB +MMCLs (KMS11, LP1 and MM.l. S) and NF-KB-MMCLS (XG7 and H9292) conferred resistance to both drugs, with an increase in 1C50 levels by approximately two to threefold relative to vector control (Fig. 2c-f and Fig. 10b). In contrast, degradative ASO-mediated PLUM repression enhanced the sensitivity of NF-KB +MMCLS (KMSll and LP1) to both BTZ and Len treatment (Fig. 10c, d). Meanwhile, NF-KB-MMCLS (XG-7 and H9292)showed no change in sensitivity to both drugs upon treatment with degradative ASOs targeting PLUM (Fig. lOe, f), suggesting the dependency on PLUM overexpression in mediating the chemoresistance function of these MMCLs. Further in vivo validation studies revealed the enhanced tumour growth and poorer survival of / 77 / -overexpressing (OE) subcutaneous tumour xenografts compared to their vector control (VC) counterparts. Moreover, PLUMOE xenografts showed increased resistance to BTZ treatment and worse survival than VC xenografts treated with BTZ (Fig. 2g-i). These observations indicate the significant role of PLUM conferring oncogenicity and chemoresistance in MM

[0226] PLUM interacts with PRC2 complex protein, EZH2, to mediate its catalytic function To understand how PLUM mediates tumorigenicity and chemoresistance in MM, its functional domains and interacting factor(s) were characterized. The exon deletion mutagenesis study showed mutants deficient in exonl and / or exon7 lose their oncogenic effects in proliferation and BTZ resistance in MMCLs (Fig. 3a, b and Fig. l la-c). Thus, RNA-protein pull down experiments were performed using three PLUM templates (Full length, AExonl and AExon7) with nuclear protein extract, followed by label-free quantitative (LFQ) mass spectrometry (MS) analysis to identify the associated RNA binding proteins (RBPs) (Fig. 3c). While the MS analysis did not display any differentially bound RBPs between FL and AExonl PLUM (Fig. 3d), deletion of AExon7 revealed a distinct list of differentially bound RBPs. Notably, EZH2, the catalytic subunit of the PRC2 complex, was identified as a PLUM interactor (Fig. 3e). The interaction was further confirmed by RNA immunoprecipitation (RIP) qPCR and microscopy-based co-localization studies using RNA FISH-IF (FISH for / 7. / / . W and IF for EZH2) (Fig. 3f, g and Fig. 1 Id).

[0227] Next, the binding of two other stoichiometric factors forming PRC2 core complex: Zeste (SUZ) 12 and embryonic ectoderm development (EED) to PLUM ' QVQ investigated by performing RNA-protein pull down assays on nuclear extracts from KMS11 and acquired BTZ resistant RPMI8226 (BTZ-R 8226) cell lines followed by immunoblotting. The data confirmed their binding to PLUM via exon7 for both cell lines (Fig. 3h and Fig. l ie). However, it was found that the binding of EED to PLUM requires both exonl and exon7. To understand the binding biochemistry of EED further, RNA-EMSA was performed using purified EED and biotinylated exonl / exon7 region of PLUM. The generated data showed direct binding of EED to exonl but not exon7, suggesting its binding to exon7 of PLUM could be indirectly mediated via EZH2 (Fig. 1 If).Further, it was then explored how the / 7. / / A / -EZH2 complex is regulated. While sh-EZH2 KD did not affect PI. M levels (Fig. 11g), KD of PLUM or overexpression of exon7 deletion mutant reduced the stability of EZH2, without affecting SUZ12 or EED levels (Fig. 3i). The impact of PLUMYM on EZH2 stability was further verified through cycloheximide (CHX) chase and MG 132 treatment assays (Fig. 3j, k). Additionally, CHX chase assay using KMS11 cells expressing exogenous EZH2, and treated with degradation ASOs (Fig. l lh), confirmed the regulation of EZH2 stability by PLUM.

[0228] Since CDK inhibitors are known targets of EZH2 that negatively regulate EZH2 activity, it was examined whether there is a regulatory feedback mechanism underlying PLUM mediated EZH2 stability and activity. ASO-mediated PLUM degradation resulted in the upregulation of CDK inhibitors (pl4 / pl5 / p21), consequently leading to the inhibition of CDKl / 2mediated EZH2 phosphorylation. This resulted in the loss of the histone methyltransferase activity of EZH2, despite its exogenous expression (Fig. 31). These observations implied PLUM interaction with EZH2 could be critical for its catalytic activity, which in turn represses the expression of CDK inhibitors.

[0229] Disordered region mediated interaction of EZH2 with PLUM is crucial for PRC2 complex formation

[0230] Given the importance of / 77 / A / -EZH2 interaction in the activity and stability of EZH2, the plausible role of this ribonucleoprotein (R P) complex in PRC2 complex formation was investigated. Through coimmunoprecipitation (co-IP) assays using sh-scramble and sh2-PLUM transduced cells in the presence of MG132 (to protect EZH2 from degradation), a diminished interaction of EZH2 with EED and SUZ12 was observed following PLUM D compared to sh-scramble controls in NF-KB+ MMCLs-KMSl 1, LP1 and BTZ-R 8226 (Fig.

[0231] 4a and Fig 12a). Interestingly, absence of EZH2 inhibited the interaction of PLUM with EED and SUZ12 whilst loss of EED or SUZ12 expression had minimal impact on binding of PLUM to EZH2 (Fig. 4b-d and Fig 12b). These findings suggested the requirement for EZH2 to interact with PLUM, thereby facilitating its binding with EED and SUZ12 to form the PRC2 complex.

[0232] To examine the biochemistry of / 7.7 / A- / -EZFI2 interaction, in-silico docking was performed using the remodelled structure of EZH2 and predicted tertiary structure of exon7 PLUMNI'&HD0CK41, thereby reconstructing the / 777A / -EZH2 RNP complex (Fig. 4e). From the docking data, the most significant interaction was observed with the C-terminal region of EZH2, 488-498 residues within the reported disordered region of EZH2 (479-515) and two additional structured regions (562-575 and 586-602) (Fig. 4e). Consistent with this, structural predictions of full-length LCA -EZH2 complex using Alphafold3 similarly revealed interaction of the disordered region of EZH2 protein (491-497 residues) with atoms in the exon 7 of PLUM (Fig. 12c). Specifically, the prediction model showed interaction of EZH2 with 994, 1000, 1001, 1002, 1003, 1010, 1011 atoms on PLUM, which are part of exon7. Previous studies have also indicated some potential RNA binding sites on mammalian PRC2 subunits, including residues 342-368 in an unstructured region of mouse EZH2 (phospho-mimic at residue 345), N-terminal residues from 32 to 42, and C terminal unstructured region from 489 to 494 in human EZH2 (in vitro binding data with G-quadruplex RNA) (Fig 4f) Next, the region on EZE12 protein having maximum potential to interact with PLUM was examined.

[0233] Having confirmed the role of PLUM on EZH2 phosphorylation (at T345 residue) and activity (Fig. 31), the corresponding role of pEZH2(T345) in binding PLIM was investigated. The pull-down data revealed reduced binding of EZH2 to PLUM in R03306 (CDK1 / 2 inhibitor) treated cells compared to DMSO (vehicle control) in both KMS11 and BTZ-R 8226 cell lines (Fig. 4g and Fig. 12d). Next, alanine scanning mutagenesis was performed within the short, structured region of EZH2 from 32 to 42 residues (HAMutl, HA-Mut2 and HA-Mut3) and employed NAAIRS (asparagine-alanine-alanine-isoleucine-arginine-serine) sequence substitution to mutate the long unstructured region of EZH2 from 489 to 494 (HA-Mut4) (Fig. 4f). It was found that HAMut2, HA-Mut3 and HA-Mut4 lost their ability to interact with PLUM compared to wild-type HA-EZH2 (Fig. 4h). The disordered region mutant, HA-Mut4 (PRKKKR498-494NAAZRS), showed most significant loss of its ability to interact with PLUM. This was further verified via RNA-EMSA using truncated Mut4-EZH2 (E317-PRKKR489-494NAAIRS-V522) protein, which showed reduced binding with biotinylated exon7 region of PLUM compared to WT EZH2 (E 17-V522). RNA-EMSA was also performed for WTEZH2 (E317-V522) and biotinylated exon7 region of PLUMv'a the presence of 200* molar excess of unlabelled exon7 region of PLUM, which competitively attenuated the binding of EZH2 to labelled exon7 region of PLUM. These findings confirm the specificity of the binding between EZH2 and exon7 of PLUM (Fig. 12e, f).To explore whether the EZH2 mutants failing to interact with PLUM could still form the PRC2 complex with SUZ12 and EED, Co-IP assays were performed in HA-WT EZH2 and HA-mutant EZH2 OE cells. While WT HA-EZH2 and HA-Mutl EZH2 showed interaction with SUZ12 and EED, this interaction was reduced for HA-Mut 2, HA-Mut 3 and HAMut 4 EZH2 (Fig. 4i). These findings suggest that the mutants unable to bind / interact with PL UM also lose their interaction with SUZ12 and EED, crucial for PRC2 complex formation. Collectively, the generated data indicate PLUM recruits PRC2 core complex factors by binding to EZH2 and suggest that this RNP complex is critical for enhancing PRC2-mediated histone trimethylation to promote myeloma functions.

[0234] Disruption of PZLZM-EZH2 interaction using steric ASOs leads to abrogation of drug resistance in MM

[0235] To explore whether the PLUM-EZH2 complex can be potentially targeted using RNA-based therapeutics like steric ASOs, the in-silico docked models of FL- / 7.7 / / V / -EZH2 was analyzed. Based on TTScorePP and TTScorePR, top three docked models were selected to identify the putative interacting regions on PLUM for targeting via steric ASOs (Fig. 5a-c). Ten steric ASOs (s-ASOs) were designed against all the interacting regions between EZH2 and PLUM (inclusive of all exons): s-ASO-g2 against exon 1, s-ASO-g3 against exon 2, s-ASO-g4 against exon 4 (Model 1 -Fig. 5a); s-ASO-g6 against exon 4, s-ASO-g7 against exon 5, s-ASO-g8 against exon 5, s-ASO-g9 against exon 9 (Model 2-Fig. 5b); s- ASO-gll against exon 6-exon 7 junction, s-ASO-gl2 against exon 7 and s-ASO-gl4 against exon 8 (Model 3-Fig. 5c). All our steric ASOs were modified with 2’-O-Methoxyethyl / locked nucleic acid (2’M0E-LNA+) chemistry (Fig. 5d). Furthermore, all the steric ASOs were tested alongside negative control (NC-ASO) for their activity to validate the in-silico docking data through RIP-qPCR using EZH2 antibody (Fig. 13a and Fig. 5e). The results showed s-ASO-gll and s-ASO-gl2 targeting exon6-exon7 junction and exon7 respectively are most effective in disrupting the / 77 / '\7-FZH2 complex, whose treatment demonstrated maximum decline in fold enrichment for PLUM in EZH2 RIP-qPCR results compared to other s-ASOs (Fig. 5e and Fig. 13a). The targeting region for s-ASO-gl 1 and s-ASO-gl2 matched the docked model 3 of PLUM-EZH2 interaction, which forms complementary pairing with fragments of exon 6-exon 7 junction and exon 7 of PLUM (Fig. 5c and Table 4). FL- / 7.7 A / -EZH2 model 3 could also recapitulate the Exon 7-PLUM-EZF12 docked model (Fig. 4e). For both the models, the residues between 489 and 494 in EZH2 interact with similar atoms on exon 7 of PLUM.Next, the selected ASOs were then assessed for their ability to impede PRC2 complex formation and downstream activity, including their impact on proliferation and drug resistance in MMCLs. Consistent with the RIP-qPCR results, s-ASO-gll and s-ASO-gl2 treatment attenuated PRC2 complex formation relative to NC-ASO in both NF-KB+ MMCLs, KMS11 and BTZ-R 8226, without affecting PLUM levels (Fig. 5f and Fig. 13b, c) In contrast, PLUM expression was reduced by approximately 30% in s-ASO-g4 treated cells (Fig. 13c), potentially affecting its reduced enrichment in RIP-qPCR experiments (Fig.

[0236] 1 a) The functional effects of s-ASO-gl 1 and s-ASO-gl 2 in KMS11 and BTZ-R 8226 cells were then examined.

[0237] Treatment of MM cells with s-ASO-gl 1 and s-ASO-gl2 reduced EZH2 activation, resulting in lowered H3K27me3 levels, which was found to be comparable to treatment using known EZH2 inhibitor (Tazemetostat) (Fig. 5g and Fig 13d) However, treatment with s-ASOs did not affect the stability of EED and SUZ12 protein (Fig. 5g). In line with the oncogenic functions of / 7T / A / -EZH2, s-ASO-gl 1 and s-ASO-gl 2 treatment reduced the proliferation of MM cells, whilst increasing the percentage of apoptotic cells (by -10%) (Fig. 5h, i and Fig. 13e, f). s-ASOs treated native and acquired resistant MMCLs also exhibited heightened sensitivity to both BTZ and Len (Fig. 5j, k). Interestingly, the effects of s-ASOs in resensitizing both native (KMS11) and acquired resistant MMCLs (BTZ-R 8226, Len-R KMS11) to chemotherapeutic drugs were similar to that of EZH2 inhibitor (Tazemetostat) (Fig. 13g, h). These findings suggest the potential use of such s-ASOs in mitigating the chemoresistance of MM, as an alternative to EZH2 inhibitors. Furthermore, the data collectively demonstrate the critical role of PLUM-EZM2 complex in mediating drug resistance in MM.

[0238] PLUM confers chemoresistance via activation of UPR pathway in MM

[0239] To unravel the molecular mechanisms mediating the functional effects of PLUM, RNA-sequencing of short hairpin RNA (shRNA)-mediated P!. UM\M and sh-scramble MM cells was performed at day 3 post transduction (before the induction of apoptosis). The analysis revealed 8153 differentially expressed genes (DEGs) upon / 7.7 / / V / [< D (adjusted p-value <= 0.05), of which 4042 and 4111 were upregulated and downregulated respectively (Fig. 6a). Several of them are involved in the regulation of metabolic processes, translational control, and ER stress pathways (Fig. 14a, b). Notably, the UPR pathway, known to regulate the balance of apoptotic and recovery signals during cancer pathogenesis in various cancer typesincluding MM, was enriched among downregulated DEGs upon P UM KD (Fig. 6b) Conversely, the expression of UPR genes (EDEM, GRP94, ATF4, Bip, CHOP) in NF-KB+ versus NF-KB- MMCLS was significantly elevated (Fig. 14c). Further analysis of the activation status of three master regulators of UPR and its downstream ATF6a target genes (Bip, HERPUD1, GRP94, PDIA4), using PLUM OE and h-PLU MMCLs, suggested that PLUM expression activates UPR pathway (Fig. 6c, d and Fig. 14d). Additionally, s-ASO-gl 1 and s-ASO-gl2 treated cells showed diminished activity of pIREla-sXBPl and EIF2a axis of UPR pathway regulation (Fig. 14e), implying the importance of P / T / A7-EZH2 interaction in driving chemoresistance in MM through UPR activation.

[0240] Hence, it was then postulated that PLUM promotes the proliferation and chemoresistance of MM via activation of UPR pathway. This was validated via shRNA KD of UPR master regulators in PLUM OE KMS11 cells, which attenuated the pro-proliferative and chemoresistance effects of PLUM. (Fig. 6e-g and Fig. 14f-h). Additionally, shRNA KD of IRE la in BTZ andLen resistant MMCLs, which displayed distinct induction of the pTREla-sXBPl axis of UPR pathway (Fig. 6h) also resensitized both cell lines to BTZ and Len treatment, respectively (Fig. 14i and Fig. 6i, j). However, in all three resistant cell lines, pEIF2a level remained low, which might be due to enhanced proliferative stress in the resistant cell lines. While previous reports have suggested the enhanced activation of eIF2a phosphatases in BTZ resistant conditions can cause MM cells to enter the quiescent phase, further studies will be needed to confirm the observed phenomenon. Overall, our findings highlight the crucial role of UPR pathway activation in augmenting the oncogenic functions of PLUM\n MM.

[0241] PLUM augments myeloma progression and chemoresistance via PRC2 mediated hypermethylation of FOXO3 / ZFP36

[0242] Next, to identify PL UM regulated targets of PRC2 complex that mediate chemoresistance in myeloma, H3K27me3 ChlP-seq in sh-scramble versus sh-PLUM KD KMS11 cells was performed. Notably, PLUMYM induced the global downregulation of H3K27me3 marks at the transcription start sites (TSS) of EZH2 bound genes (Fig. 7a). Further integration of the lost H3K27me3 peaks with the nearest upregulated DEGs from h-PLUM RNA-seq data revealed several genes enriched in processes related to mRNA metabolism, cell cycle control and protein stability / apoptosis (Fig. 7b and Fig. 15a). Since earlier observations indicate PLUM mediates chemoresistance via activation of UPR pathway, (Fig. 6), it was postulatedthat this may be regulated via the epigenetic functions of EZH2. To select putative PLUM regulated EZH2 targets involved in UPR-mediated chemoresistance, it was then focused on genomic loci exhibiting reduced H3K27me3 marks at the TSS of cancer associated genes. Two uncharacterized targets of EZH2, FOXO3 and ZFP36 were identified, which have been previously implicated in the repression of UPR pathway in other cancer types. Both targets display reduced H3K27me3 marks at their gene loci following PLUM KD (Fig. 7c), indicating they could be potentially regulated by ZMW-EZH2 complex.

[0243] In line with this, PLUM OE in KMS11 cells induced H3K27 trimethylation at the TSS of FOXO3 and ZFP36, which in turn repressed their protein expression (Fig. 15b-d). Conversely, s -PLUM KD or overexpression of PLUM AExonl and AExon7 resulted in the reduced H3K27me3 enrichment of both targets, along with the induction of their protein expression (Fig. 15d-f). These findings demonstrate that PLUM regulates FOXO2 and ZFP36 expression by enhancing the H3K27 trimethylation activity of PRC2, plausibly via its interaction with PRC2 core complex factors, EZH2 and EED It was then investigated whether both PLUM-EZM2 regulated targets are involved in the chemoresistance of MM. Here, it was found that BTZ and Len resistant MMCLs displayed elevated H3K27 trimethylation of both targets, along with their reduced protein expression levels, compared to parental, sensitive cells (Fig. 7d-f). This is consistent with their elevated expression of PLUM. Notably, treatment of resistant MMCLs with s-ASO-gl2 resulted in the loss ofH3K27me3 enrichment at both gene targets, which correlated with their induced protein expression (Fig. 7g-i). These data validated the role of / T / A -EZH2 complex in regulating FOXO2 and ZFP36 expression in resistant MMCLs.

[0244] To further verify the role of FOXO3 and ZFP36 in modulating UPR mediated chemoresistance in MM, the activation of UPR pathway regulators was examined following shRNA-mediated KD of both genes in parental KMS 11 cells FOXO3 or ZFP36 KD induced both the IRElot-sXBPl and eIF2a axis of UPR pathway, correlating with the enhanced proliferation and increased resistance of shRNA targeted cells to BTZ treatment relative to sh-scramble cells (Fig. 7j, k and Fig. 15g-j). These findings are in line with earlier findings on the regulation of UPR pathway driven chemoresistance by PLUM Fg. 6).

[0245] Subsequently, the therapeutic efficacy of the designed s-ASOs were then evaluated in vivo, using subcutaneous tumour xenografts M PLUM OE KMS 11 cells. Consistent with the invitro data, s-ASO-gl2 treated xenografts displayed reduced tumour growth compared to ASO-NC treated xenografts. Furthermore, combination treatment with s-ASO-gl2 and BTZ led to further reduction in tumour volume compared to s-ASO-gl2 or BTZ treatment alone (Fig. 71 and Fig. 16a, b). In accordance with tumour load, PLUM OE engrafted mice treated with combination of s-ASO-gl2 and BTZ showed significantly higher survival rate compared to s-ASO-gl2, BTZ and ASO-NC treatment alone groups (Fig. 7m). These findings confirm the potential of targeting PLUM-EZH2 complex as a strategy to mitigate the therapeutic resistance of MM patients Additionally, a regulatory mechanism was revealed for this RNP complex in MM, acting through the enhanced H3K27me3 activity of PRC2 complex, which in turn drives chemoresistance via the FOXO3 / ZFP36 / UPR pathway axis (Fig. 7n).

[0246] Collectively, the data confirmed an epigenetically regulated IncRNA, PLUM, which interacts with EZH2, facilitating PRC2 complex formation and epigenetic functions to promote UPR pathway mediated chemoresistance in MM. Additionally, the use of mixmer ASOs was identified as a potential therapeutic tool to target specific lncRNA-EZH2 interactions, providing a unique strategy to disrupt the oncogenic functions of PRC2-associated RNPs.

[0247] Table 1: List of shRNA sequences

[0248]

[0249]

[0250] Table 2: List of qPCR primers

[0251]

[0252] Table 3: List ChIP qPCR primers

[0253]

[0254] Table 4: The designed steric ASOs and respective targeting exons along with sequences on PLUM based on predicted interacting regions between FL PLUM-EZH2 docked models (Model 1, Model 2 and Model 3).

[0255]

[0256] It will be appreciated that many further modifications and permutations of various aspects of the described embodiments are possible. Accordingly, the described aspects are intended to embrace all such alterations, modifications, and variations that fall within the spirit and scope of the appended claims.

Claims

CLAIMS1. A method of treating a cancer in a subject in need thereof, comprising administering a pharmaceutically effective amount of a nucleic acid inhibitor of a long non-coding RNA (IncRNA), LINC02362, wherein the nucleic acid inhibitor is capable of inhibiting the interaction between LINC02362 and an Enhancer of Zeste Homolog 2 (EZH2) polypeptide.

2. The method of claim 1, wherein the nucleic acid inhibitor is selected from the group consisting of a small interfering RNA (siRNA), an antisense nucleic acid (ASO), and a short hairpin RNA (shRNA).

3. The method of claim 1 or 2, wherein the nucleic acid inhibitor comprises, encodes, or binds to a nucleic acid sequence having at least 70% sequence identity to a nucleic acid sequence in any one of SEQ ID NOs: 19-20, or a complementary sequence thereof.

4. The method of any one of claims 1 to 3, wherein the nucleic acid inhibitor comprises, encodes, or binds to a nucleic acid sequence having at least 70% sequence identity to a nucleic acid sequence in any one of SEQ ID NOs: 2-4, 6-9, 11, 12, 14, or a complementary sequence thereof:CTCCAGAAGGAGTTGAGAATG (SEQ ID NO: 2);GAGTGAAAAATCCAAGGT (SEQ ID NO: 3);GT ATC AGC ATC TATTTC A (SEQ ID NO: 4);GCCATTATTTTAAGAAGAC T (SEQ ID NO: 6);CGTGTTGACCAGACTGAT (SEQ ID NO: 7);AGATTATAGGTGTGAGCC (SEQ ID NO: 8);GCTTCATGTACAGCCTGTAG (SEQ ID NO: 9);CAGATAAGGCAGCACAGG (SEQ ID NO: 11);CGGTGGGAGGTGTTTGGATTG (SEQ ID NO: 12);CTAGCAGCATCATCCGCTCC (SEQ ID NO: 14).

5. The method of any one of claims 1 to 3, wherein the nucleic acid inhibitor is capable of binding specifically to a nucleic acid sequence of SEQ ID NO: 21.

6. The method of any one of claims 1 to 3, wherein the nucleic acid inhibitor is capable ofinhibiting the interaction between a nucleic acid sequence having at least 70% sequence identity to a nucleic acid sequence in SEQ ID NO: 21 and the EZH2 polypeptide.

7. The method of any one of claims 1 to 6, wherein the nucleic acid inhibitor is a nucleic acid molecule comprising at least 70% sequence identity to any one of SEQ ID NOs: 15- 16, or a complementary sequence thereof:GUCUAUUCCGUCGUGUCC (SEQ ID NO: 15);GCCACCCUCCACAAACCUAAC (SEQ ID NO: 16).

8. The method of any one of claims 1 to 7, wherein the nucleic acid inhibitor is a steric antisense nucleic acid.

9. The method of any one of claims 1 to 8, wherein the nucleic acid inhibitor comprises at least a modified nucleic acid residue selected from a group comprising phosphorothioate (PS) linkage modification, sugar moiety modification, locked nucleic acid (LNA), or a combination thereof.

10. The method of claim 9, wherein the sugar moiety modification is a 2’-O-Methoxyethyl (2’MOE) modification.

11. The method of any one of claims 1 to 10, wherein the nucleic acid inhibitor is a nucleic acid molecule comprising at least 70% sequence identity to any one of SEQ ID NOs: 17- 18, or a complementary sequence thereof:5’-mG*mT*C*mT*mA*mT*mT*C*C*mG*mT*C*mG*mT*mG*mT*C*C-3’(SEQ ID NO: 17);5’-mG*mC*mC*mA*mC*mC*mC*mT*mC*mC*mA*mC*mA*mA*mA*mC* mC*mT*mA*mA*mC-3’ (SEQ ID NO: 18), wherein:m = 2’ -O-M ethoxy ethyl (2’MOE) modification;* = phosphorothioate (PS) linkage; andunderline = locked nucleic acid.

12. The method of any of claims 1 to 11, wherein the nucleic acid inhibitor is provided in a pharmaceutically acceptable carrier.

13. The method of any one of claims 1 to 12, wherein the subject is found to be chemoresistant to a drug therapy.

14. The method of any one of claims 1 to 13, wherein the subject is found to be non- responsive to an EZH2 inhibitor therapy.

15. The method of any one of claims 1 to 14, wherein the cancer is a blood cancer or a solid tumor.

16. The method of claim 15, wherein the blood cancer is myeloma or lymphoma.

17. The method of claim 15, wherein the solid tumor is a breast cancer, prostate cancer, ovarian cancer, cervical cancer, pancreatic cancer, colorectal cancer, lung cancer, hepatocellular cancer, gastric cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, brain cancer, non-small cell lung cancer, squamous cell cancer of the head and neck, endometrial cancer, rectal cancer, and esophageal cancer.

18. The method of any one of claims 1 to 17, wherein the cancer is a cancer that overexpresses EZH2 and / or LINC02362 as compared to a reference.

19. A nucleic acid inhibitor of L1NC02362, wherein the nucleic acid inhibitor of L1NC02362 comprises, encodes, or binds to a nucleic acid sequence having at least 70% sequence identity to a nucleic acid sequence in any one of SEQ ID NOs: 19-20, or a complementary sequence thereof.

20. The nucleic acid inhibitor of LINC02362 of claim 19, wherein the nucleic acid inhibitor of LINC02362 comprises, encodes, or binds to a nucleic acid sequence of having at least 70% sequence identity to any one of SEQ ID NOs: 2-4, 6-9, 11, 12, 14, or a complementary sequence thereof:CTCCAGAAGGAGTTGAGAATG (SEQ ID NO: 2); GAGTGAAAAATCCAAGGT (SEQ ID NO: 3); GTATCAGCATCTATTTCA (SEQ ID NO: 4); GCCATTATTTTAAGAAGACT (SEQ ID NO: 6);CGTGTTGACCAGACTGAT (SEQ ID NO: 7);AGATTATAGGTGTGAGCC (SEQ ID NO: 8); GCTTCATGTACAGCCTGTAG (SEQ ID NO: 9); CAGATAAGGCAGCACAGG (SEQ ID NO: 11);CGGTGGGAGGTGTTTGGATTG (SEQ ID NO: 12);CTAGCAGCATCATCCGCTCC (SEQ ID NO: 14).

21. The nucleic acid inhibitor of LINC02362 of claim 19 or 20, wherein the nucleic acid inhibitor is a nucleic acid molecule comprising at least 70% sequence identity to any one of SEQ ID NOs: 15-16, or a complementary sequence thereof:GUCUAUUCCGUCGUGUCC (SEQ ID NO: 15);GCCACCCUCCACAAACCUAAC (SEQ ID NO: 16).

22. The nucleic acid inhibitor of LINC02362 of any one of claims 19 to 21, wherein the nucleic acid inhibitor comprises at least a modified nucleic acid residue selected from a group comprising phosphorothioate (PS) linkage modification, sugar moiety modification, locked nucleic acid (LNA), or a combination thereof.

23. The nucleic acid inhibitor of LINC02362 of claim 22, wherein the sugar moiety modification is a 2’-O-Methoxyethyl (2’MOE) modification.

24. The nucleic acid inhibitor of L1NC02362 of any one of claims 19 to 23, wherein the nucleic acid inhibitor is a nucleic acid molecule comprising at least 70% sequence identity to any one of SEQ ID NOs: 17-18, or a complementary sequence thereof:5’-mG*mT*C*mT*mA*mT*mT*C*C*mG*mT*C*mG*mT*mG*mT*C*C-3’(SEQ ID NO: 17);5’-mG*mC*mC*mA*mC*mC*mC*mT*mC*mC*mA*mC*mA*mA*mA*mC* mC*mT*mA*mA*mC-3’ (SEQ ID NO: 18), wherein:m = 2’-O-Methoxyethyl (2’MOE) modification;* = phosphorothioate (PS) linkage; andunderline = locked nucleic acid.

25. A method of detecting a cancer with drug resistance in a subject, the method comprising: (a) detecting the level of expression of EZH2 and / or LINC02362 in a sample from the subject, wherein an increased expression of EZH2 and / or L1NC02362 as compared to a reference indicates that the subject is likely to have the cancer with drug resistance; and (b) administering a pharmaceutically effective amount of a nucleic acid inhibitor of LINC02362 to the subject found likely to have the cancer with drug resistance.

26. Use of a nucleic acid inhibitor of LINC02362 in the manufacture of a medicament for treating a subj ect with a cancer.

27. A nucleic acid inhibitor of LINC02362, for use in the treatment of a cancer.

28. A pharmaceutical composition comprising a nucleic acid inhibitor of LINC02362 for use in the treatment of a cancer.

29. Use of a pharmaceutical composition comprising nucleic acid inhibitor of LINC02362 in the manufacture of a medicament for a cancer.